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1. INTRODUCTION 
  
 Pharmaceutical formulation, in pharmaceutics, is the process in which 
different chemical substances, including the active drug, are combined to produce a 
final medicinal product. 
Formulation studies involve developing a preparation of the drug which is both 
stable and acceptable to the patient. For orally taken drugs, this usually involves 
incorporating the drug into a tablet or a capsule. It is important to appreciate that a 
tablet contains a variety of other substances apart from the drug itself, and studies 
have to be carried out to ensure that the drug is compatible with these other 
substances. 
A tablet is usually a compressed preparation that contains: 
 5-10% of the drug (active substance); 
 80% of fillers, disintegrants, lubricants, glidants, and binders; and 
 10% of compounds which ensure easy disintegration, disaggregation, and 
dissolution of the tablet in the stomach or the intestine. 
 
Fixed-dose combinations (FDCs)
1
 
 
The development of fixed-dose combinations (FDCs) is becoming increasingly 
important from a public health perspective. Such combinations of drugs are being 
used in the treatment of a wide range of conditions and are particularly useful in the 
management of HIV/AIDS, malaria and tuberculosis, which are considered to be 
the foremost infectious disease threats in the world today. 
Definition 
 
A combination drug or fixed-dose combination (FDC) is a formulation of two or 
more active ingredients combined in a single dosage form, available in certain fixed 
doses. When the drug product is a "pill" (e.g., tablet or capsule for oral 
consumption) the FDC product can also be called a "polypill." 
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Recently, in India Fixed Dose Combination (FDC) of Drugs / medicines has drawn 
the attention of health  service  providers and the service recipients.  A fixed dose 
combination (FDC) is a formulation of two  or more active ingredients combined in 
a single dosage  form available in certain fixed doses. Fixed dose combination drug 
products may improve medication compliance of  patients. Fixed dose combination 
drugs are also developed  to target a single disease like AIDS, TB and malaria.  
Some of the FDCs are reviewed by the FDA and the active ingredients used therein 
are not expected to interact  adversely with each other, but may interact with other 
drugs  that a patient is taking. Though FDCs may reduce burden  of consuming more 
pills, there are some disadvantages.  Like, if a patient needs dosage adjustment, the 
existing FDC  may not suit the most appropriate strength for the patient.  Further, 
after using an FDC if an adverse drug reaction  occurs, it may be difficult to identify 
the active ingredient  responsible for causing the reaction.  A pharmaceutical 
company may develop a FDC with the  sole aim of marketing advantage of 
exclusive rights to sell  the FDC, even though the individual active ingredients may  
be off-patent. When more than two drugs are combined,  the cumulative toxicity and 
risk-benefits of the new product  need to be examined before marketing such 
products. 
 
FDC & Infectious Diseases 
There is emergence of previously unreported infectious diseases and re-emergence 
of infectious diseases thought to be on the way to elimination. There is also evidence 
of infectious pathogens exhibiting antimicrobial resistance even in multiple-drug 
usage. 
Advantages and disadvantages of fixed-dose combinations  
Advantages  
 Simpler dosage schedule improves compliance and therefore improves 
treatment outcomes 
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 Reduces inadvertent medication errors  Prevents and/or slows attainment of 
antimicrobial resistance by eliminating  monotherapy (i.e, one drug   is never 
by itself in circulation) 
 Allows for synergistic combinations (i.e., trimethoprim / sulfamethoxazole 
combination allows each drug to selectively interfere with successive steps in  
bacterial folate metabolisms 
 Eliminates drug shortages by simplifying drug storage and  handling, and 
thus lowers risk of being “out of stock” 
 Only 1 expiry date simplifies dosing (single products  may have different 
expiry dates)  
 Procurement, management and handling of drugs is simplified 
 Lower packing and shipping costs 
 Less expensive than single ingredient drugs 
 Side effects are reduced by using one drug of the combination for this 
purpose 
 Potential for drug abuse can be minimized by using one drug of the 
combination for this purpose (i.e., excessive use of the antidiarrheals ). 
Disadvantages 
 
 FDCs are (possibly) more expensive than separate tablets 
 Potential quality problems, especially with rifampicin in FDCs for TB, 
requiring bio-availability testing 
 If a patient is allergic or has a side-effect to 1 component, the FDC must be 
stopped and replaced by separate tablets 
 Dosing is inflexible and cannot be regulated to patient’s needs (each patient 
has unique characteristics such as weight, age, pharmacogenetics, co-
morbidity, that may alter drug metabolism and effect).  
 Incompatible pharmacokinetics is irrational because of different elimination 
½ lives of individual components 
 Reaction of one of the components (e.g., a rash to sulfamethoxazole in 
cotrimoxazole) may result in patient avoiding the “innocent” trimethoprim in 
the future  
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 Drug interactions may lead to alteration of the therapeutic effect. 
 Combinations make therapeutic sense for HIV, TB and malaria, but the 
evidence for the utility of combinations is still largely circumstantial.  
 The products should have therapeutic rationale and are safe, to remain in the 
market. Poly-pills are used in the UK for primary prevention of heart 
diseases. Multiple components of FDCs can lead to complex issues of IPR 
access and global IP rules. 
Tablets:
6,7
 
 Tablets are solid oral dosage forms usually prepared with the aid of 
suitable pharmaceutical excipients.  They may vary in size, shape, weight, hardness, 
thickness, disintegration, dissolution characteristics and in other aspects, depending 
on their intended use and method of manufactures. 
1.1. ADVANTAGES
16
 
Tablets are simple and convenient to use. They provide an accurately measured 
dosage of the active ingredient in a convenient portable package, and can be 
designed to protect unstable medications or disguise unpalatable ingredients. 
 Colored coatings, embossed markings and printing can be used to aid tablet 
recognition. Manufacturing processes and techniques can provide tablets 
special properties, for example, sustained release or fast dissolving 
formulations.  
 
 Noninvasive 
 
 Portability 
 
 Hard to tamper with tablets 
 
 Easy to swallow, especially if coated. 
 
 Relatively easy to manufacture and package 
 
 Provide accurate dosing 
 
 Increased stability of the drug when compared to liquid dosage forms. 
 
 Product identification is easy especially with use of imprints. 
 5 
 
 
 Can be enteric coated or designed for delayed release. 
 
 Offers greatest capability of all oral dosage forms for the greatest dosage                                                                   
precision & least content Uniformity.  
  
 High patient compliance. 
 Their cost is lowest of all dosage forms 
 One of the major advantages of tablet over capsules is that the tablet is       
essentially “tamperproof dosage form”. 
 Easiest and cheapest to packaging and shipment 
 They are having best combined properties of chemical, mechanical and 
microbiological properties 
 Accuracy of dose is maintained since tablet is a solid unit dosage forms 
 Longer expiry period and minimum microbial spillage owing to lower 
moisture content 
 Large scale manufacturing is feasible in comparison to other dosage forms. 
Therefore, economy can be achieved. 
 Organoleptic properties (taste, appearance, and odor) are improved by 
coating of the tablets. Product identification is easy and marketing done with 
the help of grooved punches and printing with edible ink. 
 As a tablet is not a sterile dosage form, stringent environmental conditions 
are not required in the tablet department. 
1.2. DISADVANTAGES 
 Drugs with poor wetting, slow dissolution property, large dosages or any 
combination of these features may be difficult or impossible to formulate & 
manufacture as a tablet. 
 It is difficult to convert a high dose poorly compressible API into a tablet of 
suitable size for human use. 
 Slow onset of action as compared to parenterals, liquid orals and capsules. 
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Fig No.1 
 
 
CLASSIFICATION OF TABLETS 
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1.3. TYPES AND CLASSES OF TABLETS:
8,14,17,18
 
Tablets are classified by their route of administration or function, by the type of drug 
delivery system they represent within that route, by their form and method of 
manufacture. 
 1.3.1. Tablets ingested orally: 
 Compressed tablets: 
These tablets are uncoated and made by compression of granules. These tablets are 
usually intended to provide rapid disintegration and drug release. These tablets 
contain water-soluble drugs, which after swallowing get disintegrated in the 
stomach, and its drug contents are absorbed in the gastrointestinal tract and 
distribute in the whole body. 
Multiple compressed tablets:  
These tablets are prepared to separate physically or chemically incompatible 
ingredients or to produce repeat action prolonged action products. To avoid 
incompatibility, the ingredients of the formulation except the incompatible materials 
are compressed into a tablet then incompatible substance along with necessary 
excipients are compressed tablet. 
 Multilayered tablets: 
These tablets consist of two or more layer of materials compressed successively in 
the same tablets. The color of each layer may be the same or different. The tablets 
having layers of different colours are known as "multicoloured tablets". 
 Sustained action tablets:  
These tablets are used to get a sustained action of medicament. These tablets when 
taken orally release the medicament in a sufficient quantity as and when required 
maintaining the maximum effective concentration of the drug in the blood through 
out the period of treatment 
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 Enteric-coated tablets: 
These are compressed tablets meant for administration by swallowing and are 
designed to bypass the stomach and get disintegrated in the intestine only. These 
tablets are made to release the drug undiluted and in the highest concentration 
possible within the intestine. Eg: tablets containing anthelmentics, and amoebic ides. 
 Sugar coated tablets: 
The compressed tablets having a sugar coating are called "sugar coated tablets". 
 Film coated tablets: 
The compressed tablets having some polymer substance, such as hydroxy propyl 
cellulose, hydroxy propyl methylcellulose, and ethyl cellulose. 
 Chewable tablets:  
These tablets are chewed in the mouth and broken into small pieces. In this way, the 
disintegration time is reduced and the rate of absorption of the medicament is 
increased. e.g.: aluminium hydroxide tablets, and phenolphthalein tablets. 
1.3.2. Tablets used in oral cavity: 
Buccal Tablets: 
These tablets are to be placed in the buccal pouch or between the gums and lips or 
cheek where they dissolve or disintegrate slowly and are absorbed directly without 
passing into the alimentary canal. Eg: tablets of ethisterone. 
 Sublingual tablets: 
These tablets are to be placed under the tongue where they dissolve or disintegrate 
quickly and are absorbed directly without passing into GIT.  
Eg: tablets of glyceryl trinities. 
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 Lozenge and Torches:  
These tablets are designed to external local effect in the mouth or throat. These 
tablets are commonly used to treat sore throat or to control coughing in common 
cold. They may contain local anaesthetics antiseptic, antibacterial agents, astringent 
and antitussives. 
 1.3.3. Tablets used to prepare solution: 
 Effervescent tablets:  
In addition to the drug substance, these contain sodium bicarbonate and an organic 
acid such as tartaric acid or citric. In the presence of water, these additives react, 
liberating carbon dioxide that acts as disintegrator and produces effervescence. 
Except for small quantities of lubricants present, effervescent tablets are soluble. 
Tablet triturates usually are made from moist material, using a triturate mild that 
gives them the shape of cut sections of cylinder. Such tablets must be completely 
and rapidly soluble; the problem arising from the compression of these tablets is the 
failure to find a lubricant that is completely water-soluble. 
 Dispensing tablets: 
These tablets provide a convenient quality of potent drug that can be incorporated 
readily in to powders and liquids, thus circumventing the necessity to weigh small 
quantities. These tablets are. Supplied primarily as a convenience for 
extemporaneous compounding and should never be dispensed as a dosage form. 
Hypodermic tablets: 
Hypodermic tablets are soft, readily soluble tablets and originally were used for the 
preparation of solutions to be injected. Since stable parenteral solutions are now 
available for most new drug substances, there is no justification for the hypodermic 
tablets for injection. Their use in this manner should be discouraged, since the 
resulting solutions are not sterile. Large quantities of these tablets continue to be 
made, but for oral administration. No hypodermic tablets ever have been recognized 
by the official compendia 
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1.3.4. Inserted Tablets: 
 Dental cones:  
These are relatively minor compressed tablets meant for placing them in the empty 
socket-after tooth extraction. They prevent the multiplication of bacteria in the 
socket following such extraction by using slow releasing antibacterial compounds or 
to reduce bleeding by containing the astringent. These cones generally get dissolved 
in 20 to 40 min time. 
 Implantation tablets:  
These tablets are placed under the skin or inserted subcutaneous by means of minor 
surgical operation and are slowly absorbed. These implants must be sterile and should 
be packed individually in sterile condition. Implants are mainly used for 
administration of hormones such as testosterone, and deoxycorticosterone etc. 
 Vaginal tablets: 
These tablets are meant to dissolve slowly in the vaginal cavity. These tablets are 
typically ovoid or pear shaped to facilitate retention in the vagina. This tablet form is 
used to release steroids, antibacterial agents, antiseptics or astringents to treat 
vaginal infections. 
The goal of any drug delivery system is to provide a therapeutic amount of drug in 
the proper site in the body to achieve promptly and then to maintain the desired   
drug concentration that is, the drug delivery system should delivery system should 
deliver drug at a rate dedicated by the needs of the body over a specified period of 
treatment. 
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1.4. EXCIPIENTS USED IN THE FORMULATION
11,12 
A compressed tablet usually consists of active medicaments mixed with a number of 
inert substances known as “excipients or additives”. These additives are added to 
give the better quality to a tablet. Although these additives are termed as inert but 
they have a great influence on stability, bioavailability and the process by which the 
dosage forms are prepared. 
 1.4.1. Excipients and their functionalities: 
Excipient means any component other than the active pharmaceutical ingredient(s) 
intentionally added to the formulation of a dosage form.  Excipients are chosen in 
tablet formulation to perform a variety of functions like 
 For providing essential manufacturing technology functions [binders, 
glidants, lubricants] 
 For enhancing patient acceptance [flavors, colourants] 
 For providing aid in product identification [colourants] 
 For optimizing or modifying drug release [disintegrants, hydrophilic 
polymers, wetting agents, biodegradable polymers] 
 For enhancing stability [antioxidant, UV absorbers] 
 1.4.2. Disintegrants:
19,28
 
Bioavailability of a drug depends in absorption of the drug, which is affected by 
solubility of the drug in gastrointestinal fluid and permeability of the drug across 
gastrointestinal membrane. The drugs solubility mainly depends on physical – 
chemical characteristics of the drug. However, the rate of drug dissolution is greatly 
influenced by disintegration of the tablet. 
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The drug will dissolve at a slower rate from a non-disintegrating tablet due to 
exposure of limited surface area to the fluid. The disintegration test is an official test 
and hence a batch of tablet must meet the stated requirements of disintegration. 
Disintegrants an important excipient of the tablet formulation, is always added to 
tablet to induce breakup of tablet when it comes in contact with aqueous fluid and 
this process of desegregation of constituent particles before the drug dissolution 
occurs, is known as disintegration process and the excipients which induce this 
process are known as disintegrants. 
The objectives behind addition of disintegrants are to increase surface area of the 
tablet fragments and to overcome cohesive forces that keep particles together in a 
tablet. 
 Mechanism of tablet disintegrants
 
The tablet breaks to primary particles by one or more of the mechanisms listed 
below:- 
 By capillary action 
 By swelling 
 Because of heat of wetting 
 Due to disintegrating particle/particle repulsive forces 
 Due to deformation 
 Due to release of gases 
 By enzymatic action 
 List of Disintegrants 
Disintegrants 
% 
Concentration  
in Tablets 
Special comments 
Starch 1500 5-15 - 
Starch USP 5-20 
Higher amount is required, poorly 
compressible 
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Avicel
® 
(PH 101, PH 102) 10-20 
Lubricant properties and directly 
compressible 
Solka floc
®
 5-15 Purified wood cellulose 
Alginic acid 1-5 Acts by swelling 
Sodium alginate 2.5-10 Acts by swelling 
Explotab
®
 2-8 Sodium starch glycolate, super 
disintegrant. 
Polyplasdone
®
(XL) 0.5-5 Crosslinked PVP 
Amberlite
®
 (IPR 88) 0.5-5 Ion exchange resin 
Methyl cellulose, Sodium 
CMC, HPMC 
5-10 - 
AC-Di-Sol
®
 1-3 Direct compression 
Carbon dioxide _ Created insitu in effervescent  
tablet 
Table No.1 
 1.4.3. SUPERDISINTEGRANTS:
20,30
 
As days passes, demand for faster disintegrating formulation is increased. So, 
pharmacist needs to formulate disintegrants i.e. Superdisintegrants which are 
effective at low concentration and have greater disintegrating efficiency and they are 
more effective intragranularly. But have one drawback that it is hygroscopic 
therefore not used with moisture sensitive drugs. 
And this superdisintegrants act by swelling and due to swelling pressure exerted in 
the outer direction or radial direction, it causes tablet to burst or the accelerated 
absorption of water leading to an enormous increase in the volume of granules to 
promote disintegration. 
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List of Super Disintegrants 
Super Disintegrants Mechanism of action Special comment 
Crosslinked cellulose 
- Swells 4-8 folds in 
 < 10 seconds. 
-Swelling and wicking 
..both. 
-Swells in two 
.dimensions. 
-Direct compression or                  
ggranulation 
-Starch free 
Crosslinked PVP 
-Swells very little and 
returns to original size 
after compression but 
act by capillary action 
-Water insoluble and 
spongy in nature so get 
porous tablet 
Crosslinked starch 
-Swells 7-12 folds in 
<30  seconds 
-Swells in three 
dimensions and high 
level serve as sustain 
release matrix 
Crosslinked alginic acid 
-Rapid swelling in 
aqueous medium or 
wicking action 
-Promote disintegration 
in both dry  or wet 
granulation 
Natural super disintegrant -- 
-Does not contain any 
starch or sugar. Used in 
nutritional products. 
 Calcium silicate 
 
-Wicking action 
-Highly porous, 
-light weight 
-optimum concentration 
is between 20-40% 
Table No.2 
 1.4.4. Diluents: 
In order to facilitate tablet handling during manufacture and to achieve targeted 
content uniformity, the tablet size should be kept above 2-3 mm and weight of tablet 
above 50 mg. Many potent drugs have low dose (for e.g. Diazepam, Clonidine 
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hydrochloride). In such cases diluents provide the required bulk of the tablet when 
the drug dosage itself is inadequate to produce tablets of adequate weight and size. 
Usually the range of diluents may vary from 5-80%. Diluents are also synonymously 
known as “fillers”. Diluents are often added to tablet formulations for secondary 
reasons like to provide better tablet properties such as: 
i) To provide improved cohesion 
ii) To allow direct compression manufacturing 
iii) To enhance flow 
iv) To adjust weight of tablet as per die capacity 
Classification of diluents:
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Tablet diluents or fillers can be divided into following categories: 
i) Organic Materials - Carbohydrate and modified carbohydrates. 
ii) Inorganic Materials – Calcium phosphates and others. 
iii) Co-processed Diluents. 
Carbohydrate substances such as sugars, starches and celluloses may also function 
as binders during wet granulation process. Whereas when used in direct compression 
system, they serve as the diluents. The inorganic diluents do not exhibit binding 
properties when used in wet granulation and direct compression. 
Tablet diluents or filler may also be classified on the basis of their solubility in 
water. 
 List of Diluents/fillers 
Insoluble tablet fillers or diluents Soluble tablet fillers or diluents 
Starch 
Powdered cellulose 
Microcrystalline cellulose 
Calcium phosphates, etc. 
Lactose 
Sucrose 
Mannitol 
Sorbitol, etc. 
Table No.3 
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Selection of diluent should be done after considering the properties of diluent such 
as: Compactibility, flowability, solubility, disintegration qualities, hygroscopicity, 
lubricity and stability. 
 1.4.5. Binders: 
Binders are added in tablet formulation to have required flow property and 
compressibility of powders. 
List of Binders 
Sugars Natural  binders Synthetic/Semi synthetic Polymer 
Sucrose Acacia Methyl Cellulose 
Liquid  glucose Tragacanth Ethyl Cellulose 
  Gelatin 
Hydroxy Propyl Methyl Cellulose  
( HPMC) 
  Starch  Paste Hydroxy Propyl  Cellulose 
  Pregelatinized  Starch Sodium Carboxy  Methyl  Cellulose 
  Alginic  Acid Polyvinyl Pyrrolidone (PVP) 
  Cellulose Polyethylene  Glycol (PEG) 
    Polyvinyl  Alcohols 
    Polymethacrylates 
Table No.4 
 1.4.6. Glidants: 
Guidant’s are added to the formulation to improve the flow properties of the material 
which is to be fed into the die cavity and aid in particle rearrangement within the die 
during the early stages of compression. If the flow properties are extremely poor 
then glidants are ineffective and consideration of force free mechanisms may be 
necessary. Starch is a popular glidant because it has additional value of disintegrant. 
Concentration of starch is common up to 10%, but should be limited otherwise it 
will worsen the flow of material. Talc is a glidant which is superior to starch but its 
concentration should be limited because it has retardant effect on dissolution-
disintegration profile. Silaceous material like colloidal silica i.e. syloid, pyrogenic 
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silica (0.25%), hydrated sodium silioaluminate (0.75%) are also successfully used to 
induce flow. 
Glidants act by interposing their particles between those of material and lower the 
overall interparticulate friction of the system by virtue of their reduced adhesive 
tendencies. Similar to lubricants, they are required at the surface of feed particles 
and they should be in fine state of division and appropriately incorporated in the 
mixture. 
 1.4.7. Anti-adherents: 
Some material have strong adhesive properties towards the metal of punches and 
dies and also the tablet formulation containing excessive moisture which has 
tendency to result in picking and sticking problem. Therefore antiadherents are 
added, which prevent sticking to punches and die walls. Talc, magnesium stearate 
and corn starch have excellent antiadherent properties. Silicon oil can also be used 
as antiadherent. 
 List of anti adherents 
Anti adherent 
% 
Concentration 
Comment 
Talc 1 – 5 
Lubricant with excellent 
antiadherents properties 
Cornstarch 3 – 10 
Lubricant with excellent 
antiadherents properties 
Colloidal silica 0.1 – 0.5 
Does not give satisfactory results 
due to small surface area. Cab-O-
Sil
®
 and Syloid
®
 
DL-Leucine 3 – 10 
Water soluble lubricant; excellent 
antiadherents properties 
Sodium lauryl 
sulphate 
<1 
Antiadherents with water soluble 
lubricant 
Stearates <1 
Antiadherents with water insoluble 
lubricant 
Table No.5 
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1.4.8. Lubricants 
Lubricants are the agents that reduce friction by interposing an intermediate layer 
between the tablet constituents and the die wall during compression and ejection. 
Solid lubricants act by boundary mechanism which results from the adherence of the 
polar portions of molecules with long carbon chains to the metal surfaces to the die 
wall. Magnesium stearate is an example of boundary lubricant. Other process is 
hydrodynamic mechanism i.e. fluid lubrication where two moving surfaces are 
separated by a finite and continuous layer of fluid lubricant. Since adherence of solid 
lubricants on the die wall is more than that of fluid lubricants, solid lubricants are 
more effective and more frequently used. 
Classification of lubricants: 
Lubricans are classified according to their water solubility i.e. water insoluble and 
water soluble. Selection of lubricant depends partly on mode of administration, type 
of tablet, desired disintegration and dissolution properties, physicochemical 
properties of granules or powder and the cost. 
I. Water insoluble lubricants: 
Water insoluble lubricants are most effective and used at low concentration than 
water soluble lubricants. Since these lubricants function by coating , their 
effectiveness is related with their surface area, extent of particle size reduction, time, 
procedure of addition and length of mixing. 
List of insoluble lubricants 
Insoluble lubricants %Concentration Comments 
Stearates (Magnesium 
Stearate, Calcium Stearate, 
Sodium stearate) 
0.25 -1 
Reduce tablet strength; 
prolong disintegration; 
widely used. 
Talc 1 -2 
Insoluble but not 
hydrophobic; moderately 
effective. 
Sterotex 0.25 – 1 - 
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Waxes 1 – 5 - 
Stearowet 1 – 5 - 
Glycerylbehapate 
(Compritol
®
888) 
1 – 5 Both lubricant and binder; 
Liquid paraffin Up to 5 
Dispersion problem; inferior 
to stearates 
Table No.6 
II. Water soluble lubricants: 
Water soluble lubricants are used when a tablet is completely soluble or when 
unique disintegration and dissolution characteristics are required. Tablet containing 
soluble lubricant shows higher dissolution rate than tablet with insoluble lubricants. 
Physical mixture of this lubricants i.e. SLS or MLS with stearates can lead to the 
best compromise in terms of lubricity, tablet strength and disintegration. 
 List of soluble lubricants 
Water soluble lubricants % Concentration 
Boric acid 1 
Sodium benzoate 5 
Sodium oleate 5 
Sodium acetate 5 
Sodium Lauryl Sulfate (SLS) 1 – 5 
Magnesium Lauryl Sulfate (MLS) 1 – 2 
Table No.7 
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1.5.  MANUFACTURING METHOD
9
 
There are four general methods of tablet preparation. 
 Direct compression  
 Wet granulation method 
 Dry granulation method 
 Fluidized bed granulation 
In the tablet-pressing process, it is important that all ingredients be dry, powdered, 
and of uniform grain size as much as possible. The main guideline in manufacture is 
to ensure that the appropriate amount of active ingredient is equal in each tablet so 
ingredients should be well-mixed. Compressed tablets are exerted to great pressure 
in order to compact the material. If a sufficiently homogenous mix of the 
components cannot be obtained with simple mixing, the ingredients must be 
granulated prior to compression to assure an even distribution of the active 
compound in the final tablet. Two basic techniques are used to prepare powders for 
granulation into a tablet: wet granulation and dry granulation. Powders that can be 
mixed well do not require granulation and can be compressed into tablets through 
Direct Compression. 
 1.5.1. Direct Compression Method:
15 
Direct compression method does not involve any addition of fluid before the 
compression of the tablets. This method should be the first choice of any tablet 
formulation because of its uncomplicated manufacturability and cost effectiveness. 
Other advantages of this technique are getting the drug product with less 
disintegration time and faster dissolution rate, better stability of an API in a drug 
product due to less processing steps and a good choice for moisture sensitive drug. 
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A tablet can be made by direct compression method in the following way, 
 
 Sift an API, diluent /diluents, binder, disintegrant, lubricant, others 
separately through sieves of an appropriate pore size. 
 Transfer the above mixer except lubricant in a blender of appropriate 
capacity. Note that the occupancy in the blender should be at least 30 % to 
the maximum of 70 % of total capacity. More occupancy will lead to 
improper mixing whereas very less occupancy will lead to segregation of 
materials. 
 For higher dose drugs normally 10 to 15 minutes of mixing is sufficient. 
 At the end of the blending process, add lubricant and mix the blend for the 
appropriate time. Avoid mixing lubricant for longer period of time as it may 
increase the hydrophobicity of the blend by coating API and other 
ingredients. 
 For lower dose drugs, fix the blending time by gradually increasing the time 
of mixing say every 10 minutes. Collect the samples from five different 
points (four corners and one in the center) in a blender every 10 minutes. 
Collect the samples till 30 to 45 minutes. 
 Analyze the sample for content uniformity. Choose the blending time at 
which you get a good content uniformity. 
1.5.2. Granulation method:
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Granulation method is used to get the granules of uniform and equal size in order to 
avoid variation in filling of dies in compression machines which in turn avoids the 
variation in tablet weight. 
Generally there are two methods of granulation adopted in industries: 
 
 1.5.2. a. Dry Granulation Technique: 
By dry granulation technique, the powder mixture is compacted in large pieces and 
subsequently broken down or sized into granules. For this method, either the active 
ingredient or the diluents must have cohesive properties. Dry granulation is specially 
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applicable to materials that cannot be prepared by wet granulation because they 
degrade in moisture or the elevated temperature required for drying the granules. 
Weigh API and other excipients along with lubricant and compact them through the 
roller compactor or make slugs. 
Mill the compacted blend / slugs in multi-mill or quadro comil through sieve of 
appropriate pore size. 
Mix the sieved blend with weighed quantity of lubricant in a blender for an 
appropriate time. 
Finally compress the blend into tablets. 
Note: If the materials during compaction are sticking inside the compaction machine 
then add some amount of lubricant with API and other excipients during compaction 
process itself. 
 1.5.2. b. Wet Granulation Technique: 
Wet granulation technique involves addition of fluid to form granules. Wet 
granulation technique improves the flow of the powder and increases mechanical 
strength of the tablet. Wet granulation process is used when the drug is not very 
much sensitive to moisture. Wet granulation is done in rapid mixer granulator 
(RMG) or Fluid bed process (FBP) in industries. 
I. Wet granulation using Rapid mixer granulator 
For wet granulation process, weigh the required materials separately and pass them 
through the sieve of appropriate pore size (normally ASTM Sieve no. # 30). 
Transfer the sieved materials to RMG of appropriate capacity and mix for 10 
minutes at particular RPM. The RPM of the RMG should be fixed at a point when 
slight whirlpool is visible in the blend to ensure the mixing of the blend from top to 
bottom. 
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Add the binder solution slowly to the blend within 2 to 3 minutes. Further run the 
machine for 1 minute after addition of binder for the uniform distribution of fluid in 
the blend. 
Stop the machine. Mix the blend manually with S.S. spatula or S.S. spoon. This 
process is known as racking. Racking is necessary to remove the materials which are 
stuck to the sides of RMG and caking at the bottom. 
You can further run the machine for 1 to 2 minutes after racking either adding extra 
quantity of solvent (in case granules are not formed) or without adding extra solvent 
(in case granules are almost formed). 
Document every action such as quantity of binder solution used, set RPM, time of 
addition of binder, racking, time of mixing the blend after addition of solvent, time 
of addition of extra solvent and quantity of extra solvent. These parameters are 
important for the reproducibility of the batch and understand the nature of API. 
Normally binder containing 10 % w/w of solid content is preferred. The percentage 
of solid content can be decreased or increased based on observation of granules 
formation. 
The amount of binder can be increased if the granules formed are softer and the 
amount of binder can be reduced if the granules formed are harder. 
You can use aqueous solution of binder where HPMC, HPC, PVP etc. can be used 
as binder. Out of above mentioned binders HPMC is required to be dispersed 
initially in warm water as HPMC forms lumps in cold water and takes long time to 
dissolve. 
Once the granules are formed, they are unloaded from RMG and dried in fluid bed 
drier or tray drier at a temperature where the drug will not degrade. Most of the 
drugs are stable at 60  C temperature. Generally the granules are dried till its LOD is 
less than 4 %w /w. 
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II. Wet granulation using Fluid bed processor31 
Wet granulation can also be done by using fluid bed processor. Granules made in 
FBP are uniform, porous and small in size. Granulation process in FBP is briefly 
explained below: 
The weighed and sieved ingredients [API and other excipients] are loaded in FBP 
and mixed at low blower speed for 5 minutes or more. 
Set the spray RPM, atomization pressure, blower speed, inlet temperature, product 
temperature and exhaust temperature. 
In the beginning, keep the blower speed low as the blend will be in powder form and 
increase in blower speed will cause the finer materials to stick to the filter bag and 
escape through the exhaust of FBP. 
Start spraying the binder solution and observe the granulation process. Spray rate of 
the binder solution can be adjusted through an observation of the granulation 
process. Avoid lumping of granules. 
At the end of granulation process dry the granules till its LOD is less that 4 % w/w. 
 1.5.3. Preparation of final blend: 
The dried granules are passed through sieve of appropriate pore size to get uniform 
granules. 
The sieved granules are lubricated with lubricant in a blender and finally 
compressed into tablets. 
 1.5.4. Compression Process:
15
 
Compression process is the final step in tablet preparation. 
 Appropriate size of punches and dies are selected and fixed in compression 
machine. 
 25 
 
 Fill the blend in the hopper. Observe the flow of the blend from hopper to the 
turret of the compression machine. 
 Initially adjust the weight of a tablet by keeping lower hardness. Once the 
weight is set, adjust the hardness and thickness of the tablet. Hardness and 
thickness are inversely proportional to each other. 
 Keep checking the weight of tablets in between the compression process. 
 Collect the tablets in appropriate container. 
 You can install dehumidifier in the compression room for moisture sensitive 
products or install sodium vapour lamp for light sensitive products. 
 1.5.5. Minitablets: 
The preparation of minitablets is similar to that of single unit tablet except the size 
of the granules is smaller and more uniform. 
For minitablet the punch and die size will be from 1 to 3 mm in size. Smaller 
granule size is necessary to avoid more void spaces between granules and avoid 
weight variation. 
Check the compression load in case of minitablets as the punches are thin and less 
stronger than bigger punches. 
Check the weight of each minitablet in between the compression process. 
Fill the Minitablets into capsules. 
 1.5.6. Dry granulation: 
This process is used when the product needed to be granulated may be sensitive to 
moisture and heat. Dry granulation can be conducted on a press using slugging 
tooling or on a roller compactor commonly referred to as a chilsonator. Dry 
granulation equipment offers a wide range of pressure and roll types to attain proper 
densification. However, the process may require repeated compaction steps to attain 
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the proper granule end point. It requires drugs or excipients with cohesive 
properties. 
 Some granular chemicals are suitable for direct compression (free flowing) 
e.g. potassium chloride. 
 Tableting excipients with good flow characteristics and compressibility allow 
for direct compression of a variety of drugs. 
 1.5.7. Fluidized bed granulation: 
It is a multiple step process performed in the same vessel to pre-heat, granulate and 
dry the powders. It is today a commonly used method in pharmaceuticals because it 
allows the individual company to more fully controls the powder preparation 
process. It requires only one piece of machinery that mixes all the powders and 
granules on a bed of air. 
Unit operations involved in wet granulation, dry granulation and direct 
compression: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. No.2 
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1.6  COMPRESSION 
 
 1.6.1. Introduction: 
 
The tablet press is a high-speed mechanical device. It 'squeezes' the ingredients into 
the required tablet shape with extreme precision. It can make the tablet in many 
shapes, although they are usually round or oval.  Also, it can press the name of the 
manufacturer or the product into the top of the tablet. Each tablet is made by 
pressing the granules inside a die, made up of hardened steel. The die is a disc shape 
with a hole cut through its centre. The powder is compressed in the centre of the die 
by two hardened steel punches that fit into the top and bottom of the die.  The 
punches and dies are fixed to a turret that spins round. As it spins, the punches are 
driven together by two fixed cams - an upper cam and lower cam. The top of the 
upper punch (the punch head) sits on the upper cam edge .The bottom of the lower 
punch sits on the lower cam edge. 
The shapes of the two cams determine the sequence of movements of the two 
punches. This sequence is repeated over and over because the turret is spinning 
round. The force exerted on the ingredients in the dies is very carefully controlled. 
This ensures that each tablet is perfectly formed. Because of the high speeds, they 
need very sophisticated lubrication systems. The lubricating oil is recycled and 
filtered to ensure a continuous supply. 
After the preparation of granules (in case of wet granulation) or sized slugs (in case 
of dry granulation) or mixing of ingredients (in case of direct compression), they are 
compressed to get final product. 
The compression is done either by single punch machine (stamping press) or by 
multi station machine (rotary press). 
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 1.6.2. Common stages occurring during compression: 
Stage 1: Top punch is withdrawn from the die by the upper cam Bottom punch 
is low in the die so powder falls in through the hole and fills the die. 
Stage 2:  Bottom punch moves up to adjust the powder weight-it raises and 
expels some powder. 
Stage 3:  Top punch is driven into the die by upper cam Bottom punch is raised 
by lower cam. Both punch heads pass between heavy rollers to 
compress the powder. 
Stage 4:  Top punch is withdrawn by the upper cam. Lower punch is pushed up 
and expels the tablet. Tablet is removed from the die surface by 
surface plate 
Stage 5:  Return to stage 1. 
 1.6.3. Auxiliary Equipments:  
Granulation Feeding Device In many cases, speed of die table is such that the time 
of die under feed frame is too short to allow adequate or consistent gravity filling of 
die with granules, resulting in weight variation and content uniformity. These also 
seen with poorly flowing granules. To avoid these problems, mechanized feeder can 
employ to force granules into die cavity. 
1.6.3.a. Tablet weight monitoring devices: 
High rate of tablet output with modern press requires continuous tablet weight 
monitoring with electronic monitoring devices like Thomas Tablet Sentinel, 
Pharmakontroll and Killan control System-MC. They monitor force at each 
compression station by strain gage technology which is then correlated with tablet 
weight. 
 1.6.3.b. Tablet Deduster: 
In almost all cases, tablets coming out of a tablet machine bear excess powder on its 
surface and are run through the tablet deduster to remove that excess powder. 
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 1.6.3.c. Fette machine: 
Fette machine is device that chills the compression components to allow the 
compression of low melting point substance such as waxes and thereby making it 
possible to compress product with low meting points. 
1.7 Packaging 
Pharmaceutical manufacturers have to pack their medicines before they can be sent 
out for distribution. The type of packaging will depend on the formulation of the 
medicine. 
'Blister packs' are a common form of packaging used for a wide variety of products. 
They are safe and easy to use and they allow the consumer to see the contents 
without opening the pack. Many pharmaceutical companies use a standard size of 
blister pack. This saves the cost of different tools and to change the production 
machinery between products. Sometimes the pack may be perforated so that 
individual tablets can be detached. This means that the expiry date and the name of 
the product have to be printed on each part of the package. The blister pack itself 
must remain absolutely flat as it travels through the packaging processes, especially 
when it is inserted into a carton. This poses interesting problems for the designers. 
Extra ribs are added to the blister pack to improve its stiffness. 
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1.8 PROBLEMS IN TABLET MANUFACTURING
10,13 
An ideal tablet should be free from any functional defect or visual defect. Functional 
defects are due to faulty formulation. Visual defect are either related to 
imperfections in any one or more of the following factors: 
 Tableting Process 
 Excipient 
 Machine 
The problems in manufacturing and their remedies are 
1.8.1. Lamination:  
Definition:  
 ‘Lamination’ is the separation of a tablet into two or more distinct horizontal layers. 
Reason:  
Air–entrapment during compression and subsequent release on ejection.The 
condition is exaggerated by higher speed of turret. 
The causes and remedies of lamination related to ‘formulation’ (Granulation) 
S.No. Causes Remedies 
1. 
Oily or waxy materials in 
granules 
Modify mixing process. Add 
adsorbent or absorbent. 
2. 
Too much of hydrophobic 
lubricant e.g.: Magnesium-
stearate. 
Use a less amount of lubricant or 
change the type of lubricant. 
Table No.8 
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 The causes and remedies of lamination related to ‘machine’ 
S.No. Causes Remedies 
1. 
Rapid relaxation of the 
peripheral regions of a 
tablet, on ejection from a 
die. 
Use tapered dies, i.e. upper part of the 
die bore has an outward taper of 3° to 
5°. 
2. Rapid decompression 
Use pre-compression step. Reduce 
turret speed and reduce the final 
compression pressure. 
Table No.9 
1.8.2. Capping: 
 
Definition: 
 
 ‘Capping’ is the term used, when the upper or lower segment of the tablet separates 
horizontally, either partially or completely from the main body of a tablet and comes 
off as a cap, during ejection from the tablet press, or during subsequent handling. 
Reason:  
 
Capping is usually due to the air–entrapment in a compact during compression and 
subsequent expansion of tablet on ejection of a tablet from a die. 
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 The causes and remedies of capping related to ‘formulation’  (granulation) 
S.No. Causes Remedies 
1. 
Large amount of fines in the 
granulation 
Remove some or all fines through 100 
to 200 mesh screen 
2. 
Too dry or very low moisture 
content 
Moisten the granules suitably. Add 
hygroscopic substance e.g.: sorbitol, 
methyl- cellulose or PEG-4000. 
3. Not thoroughly dried granules. Dry the granules properly. 
4. 
Insufficient amount of binder 
or improper binder. 
 
Increasing the mount of binder or 
Adding dry binder such as pre-
gelatinized starch, gum acacia, 
powdered sorbitol, PVP, hydrophilic 
silica or powdered sugar. 
5. 
Insufficient or improper 
lubricant. 
Increase the amount of lubricant or 
change the type of lubricant. 
Table No.10 
 The causes and remedies of capping related to ‘machine’  
(dies, punches and tablet press) 
 
S.No. Causes Remedies 
1.  Poorly finished dies 
Polish dies properly. Investigate other 
steels or other materials. 
2. 
Deep concave punches or 
beveled-edge faces of 
punches. 
Use flat punches. 
3. 
Lower punch remains 
below the face of die 
during ejection. 
Make proper setting of lower punch during 
ejection. 
4. 
Incorrect adjustment of 
sweep-off blade. 
Adjust sweep-off blade correctly to 
facilitate proper ejection. 
5. High turret speed. 
Reduce speed of turret (Increase dwell 
time). 
Table No.11 
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1.8.3. Chipping: 
Definition: 
 ‘Chipping’ is defined as the breaking of tablet edges, while the tablet leaves the 
press or during subsequent handling and coating operations. 
Reason: 
Incorrect machine settings, specially mis-set ejection take-off. 
The causes and remedies of chipping related to ‘formulation’ 
S.No. Causes Remedies 
1. Sticking on punch faces 
Dry the granules properly or increase 
lubrication. 
2. Too dry granules. 
Moisten the granules to plasticize. Add 
hygroscopic substances. 
3. 
Too much binding causes 
chipping at bottom. 
Optimize binding, or use dry binders. 
Table No.12 
The causes and remedies of chipping related to ‘machine’ 
S.No. Causes Remedies 
1. 
Groove of die worn at 
compression point.  
Polish to open end, reverse or replace the 
die. 
2. 
Edge of punch face turned 
inside/inward.  
Polish the punch edges 
3. 
Barreled die (center of the 
die wider than ends)  
Polish the die to make it cylindrical 
4. 
Concavity too deep to 
compress properly 
Reduce concavity of punch faces. Use 
flat punches. 
Table No.13 
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1.8.4. Cracking: 
Definition:  
Small, fine cracks observed on the upper and lower central surface of tablets, or very 
rarely on the sidewall are referred to as ‘Cracks’. 
Reason:  
It is observed as a result of rapid expansion of tablets, especially when deep concave 
punches are used. 
 The causes and remedies of cracking related to ‘formulation’ 
S.No. Causes Remedies 
1. Large size of granules. Reduce granule size. Add fines. 
2. Too dry granules. 
Moisten the granules properly and add 
proper amount of binder. 
3. Tablets expand. Improve granulation. Add dry binders. 
4. Granulation too cold. Compress at room temperature. 
Table No.14 
The causes and remedies of cracking related to ‘machine’ 
S.No. Causes Remedies 
1. 
Tablet expands on ejection due to air 
entrapment. 
Use tapered die. 
2. 
Deep concavities cause cracking while 
removing tablets. 
Use special take-off. 
Table No.15 
 
 
 
 35 
 
1.8.5. Sticking / Filming: 
Definition:  
‘Sticking’ refers to the tablet material adhering to the die wall. 
‘Filming’ is a slow form of sticking and is largely due to excess moisture in the 
granulation. 
Reason:  
Improperly dried or improperly lubricated granules. 
 The causes and remedies of sticking related to ‘formulation’ 
S.No. Causes Remedies 
1. 
Granules not dried 
properly. 
Dry the granules properly. Make moisture 
analysis to determine limits. 
2. 
Too little or improper 
lubrication. 
Increase or change lubricant. 
3. Too much binder 
Reduce the amount of binder or use a different 
type of binder. 
4. 
Hygroscopic granular 
material. 
Modify granulation and compress under 
controlled humidity. 
5. 
 Too soft or weak 
granules. 
Optimize the amount of binder and granulation 
technique. 
Table No.16 
The causes and remedies of sticking related to ‘machine’ 
S.No. Causes Remedies 
1. Concavity too deep for granulation. Reduce concavity to optimum. 
2. Too little pressure. Increase pressure. 
3. Compressing too fast. Reduce speed. 
 
Table No.17 
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1.8.6. Picking: 
Definition:  
 ‘Picking’ is the term used when a small amount of material from a tablet is sticking 
to and being removed off from the tablet-surface by a punch face. 
Reason: 
Picking is of particular concern when punch tips have engraving or embossing 
letters, as well as the granular material is improperly dried. 
The causes and remedies of picking related to ‘formulation’ 
S.No. Causes Remedies 
1. Excessive moisture in granules. 
Dry properly the granules, determine 
optimum limit. 
2. Too little or improper lubrication. 
Increase lubrication; use colloidal 
silica as a ‘polishing agent’, so that 
material does not cling to punch 
faces. 
3. 
Low melting point substances, 
may soften from the heat of 
compression and lead to picking. 
Add high melting-point materials. 
Use high meting point lubricants. 
4. 
Low melting point medicament in 
high concentration. 
Refrigerate granules and the entire 
tablet press. 
5. 
Too warm granules when 
compressing. 
Compress at room temperature. Cool 
sufficiently before compression. 
6. Too much amount of binder. 
Reduce the amount of binder, 
change the type or use dry binders. 
Table No.18 
 The causes and remedies of picking related to ‘machine’ 
S.No. Causes Remedies 
1. 
Rough or scratched punch 
faces. 
Polish faces to high luster. 
2. 
Embossing or engraving 
letters on punch faces such 
as B, A, O, R, P, Q, G. 
Design lettering as large as possible. Plate 
the punch faces with chromium to produce 
a smooth and non-adherent face. 
3. 
Bevels or dividing lines too 
deep. 
Reduce depths and sharpness. 
4. 
Pressure applied is not 
enough; too soft tablets. 
Increase pressure to optimum. 
Table No.19
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1.8.7. Binding: 
Definition:  
 ‘Binding’ in the die, is the term used when the tablets adhere, seize or tear in the 
die. A film is formed in the die and ejection of tablet is hindered. With excessive 
binding, the tablet sides are cracked and it may crumble apart. 
Reason:  
Binding is usually due to excessive amount of moisture in granules, lack of 
lubrication and/or use of worn dies. 
The causes and remedies of binding related to ‘formulation’ 
S.No. Causes Remedies 
1. 
Too moist granules and extrudes 
around lower punch. 
Dry the granules properly. 
2. Insufficient or improper lubricant. 
Increase the amount of lubricant or 
use a more effective lubricant. 
3. Too coarse granules. 
Reduce granular size, add more 
fines, and increase the quantity of 
lubricant. 
4. 
Too hard granules for the lubricant 
to be effective. 
Modify granulation. Reduce 
granular size. 
5. 
Granular material very abrasive 
and cutting into dies. 
If coarse granules, reduce its size. 
Use wear-resistant dies. 
6. 
Granular material too warm, sticks 
to the die. 
Reduce temperature. Increase 
clearance if it is extruding. 
Table No.20 
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The causes and remedies of binding related to machine 
S.No Causes Remedies 
1. Poorly finished dies. Polish the dies properly. 
2. 
Rough dies due to abrasion, 
corrosion. 
Investigate other steels or other materials 
or modify granulation. 
3. 
Undersized dies. Too little 
clearance. 
Rework to proper size. Increase 
clearance. 
4. 
Too much pressure in the 
tablet press. 
Reduce pressure or Modify granulation. 
 
Table No.21 
1.8.8. Mottling: 
Definition:  
 ‘Mottling’ is the term used to describe an unequal distribution of colour on a tablet, 
with light or dark spots standing out in an otherwise uniform surface. 
Reason:  
One cause of mottling may be a coloured drug, whose colour differs from the colour 
of excipients used for granulation of a tablet. 
 The causes and remedies of ‘mottling’ 
S.No. Causes Remedies 
1. 
 
A coloured drug used along 
with colourless or white-
coloured excipients. 
Use appropriate colourants. 
2. 
A dye migrates to the surface 
of granulation while drying. 
Change the solvent system, Change the 
binder, Reduce drying temperature. 
3. 
Improperly mixed dye, 
especially during ‘Direct 
Compression’. 
Mix properly and reduce size if it is of a 
larger size to prevent segregation. 
4. 
Improper mixing of a 
coloured binder solution. 
 
Incorporate dry colour additive during 
powder blending step, then add fine 
powdered adhesives such as acacia and 
tragacanth and mix well and finally add 
granulating liquid. 
Table No.22 
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1.8.9. Double impression: 
Definition:  
 ‘Double Impression’ involves only those punches, which have a monogram or other 
engraving on them. 
Reason:  
At the moment of compression, the tablet receives the imprint of the punch. On 
some machines, the lower punch freely drops and travels uncontrolled for a short 
distance before riding up the ejection cam to push the tablet out of the die. During 
this free travel, the punch rotates and at this point, the punch may make a new 
impression on the bottom of the tablet, resulting in ‘Double Impression’. 
 If the upper punch is uncontrolled, it can rotate during the short travel to 
the final compression stage and create a double impression. 
The causes and remedies of double ‘impression’ 
S.No. Causes Remedies 
1. 
Free rotation of either upper 
punch or lower punch 
during ejection of a tablet. 
-Use keying in tooling, i.e. inset a key 
alongside of the    punch, so that it fits 
the punch and prevents punch rotation.  
-Newer presses have anti-turning 
devices, which prevent punch rotation. 
Table No.23 
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DISEASE INTRODUCTION 
Malaria: 
Quartan malaria; Falciparum malaria; Biduoterian fever; Blackwater fever; Tertian 
malaria; Plasmodium 
Malaria is a tropical protozoan parasitic disease caused by Plasmodium falciparum, 
P. vivax, P. ovale and P. malariae. The disease is transmitted to human by the 
female Anopheles mosquito, during a blood meal. Of the four species P. falciparum 
is the most pathogenic responsible for about 40,000 million disability adjusted life 
years and an estimated 350–500 million malaria clinical episodes occur annually 
world wide.  
Epidemiology:  
 
Malaria causes about 400-900 million cases of fever and approximately 2-3 million 
deaths annually which represents one death every 15 seconds. The vast majority of 
cases occur in children under 5 years pregnant women are also especially vulnerable. 
Despite efforts to reduce transmission and increase treatment, there has been little 
change in areas who are at risk for the disease since 1992. In fact, if the prevalence 
of malaria continues on its course of continuous increase, the mortality rate could 
double in the next twenty years. The precise statistics are unknown because many 
cases occur in rural areas where people have no access to hospitals or resources to 
ensure health care. As a result, most cases remain undocumented.  
 
Although co-infection of HIV with malaria mortality has increased, it remains a 
minor problem that the combination of HIV – TB. 
Each year, 25-30 million people travel to tropical areas, and approximately 10,000-
30,000 US and European travelers acquire malaria. 
Around 60% of the cases and over 80% of the deaths due to malaria occur in Sub-
Saharan Africa. 
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Geographic distribution of malaria and its incidence: 
 
Malaria is endemic in most tropical and sub-tropical countries of sub-Saharan 
Africa, in large areas of the Middle East, South Asia, South East Asia, Oceania, 
Haiti, Central and South America and in parts of Mexico, North Africa and the 
Dominican Republic. It represents one of the largest scourges in third world 
countries, affecting approximately 300 - 500 million people, and killing three 
million people annually. In endemic areas, the number of malaria cases increases 
from time to time dramatically to an epidemic level. The population of Africa 
suffers the most from malaria, and it is reported that 90% of malaria cases are 
diagnosed in Africa, mainly among young children and pregnant women. It is 
reported that malaria causes the death of an African child every 30 seconds. 
 
Geographic distribution of malaria (CENTERS FOR DISEASE CONTROL 
AND PREVENTION)  
  
Fig.No.3  
 
Risk factors 
All human beings are at risk to acquire malaria. However, this tropical infection is 
more severe particularly in the following individuals: 
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 Children up to an age of 5 years 
 Adults over 65 years old 
 Pregnant women 
 People treated with steroids or those receiving chemotherapy 
 Patients with acquired HIV infection (Aids patients) 
 Splenectomized people 
 People suffering from porphyry, epilepsy or chronic illness 
International occurrence 
Malaria is responsible for approximately 1-3 million deaths per year, typically in 
children in sub-Saharan Africa infected with P falciparum. Populations at an 
increased risk for mortality due to malaria include primigravida individuals, 
travelers without immunity, and young children aged 6 months to 3 years who live 
in endemic areas.  
Worldwide, an estimated 300-500 million cases occurring annually.
[9] 
It is most 
prevalent in rural tropical areas below elevations of 1000 m [3282 ft] but is not 
limited to these climates. P falciparum is found mostly in the tropics and accounts 
for about 50% of cases and 95% of malarial deaths worldwide. P vivax is distributed 
more widely than P falciparum, but it causes less morbidity and mortality; however, 
both P vivax and P ovale can establish a hypnozoite phase in the liver, resulting in 
latent infection.  
Human immunodeficiency virus [HIV] and malaria co-infection is a significant 
problem across Asia and sub-Saharan Africa, where both diseases are relatively 
common. Evidence suggests that malaria and HIV co-infection can lead to worse 
clinical outcomes in both disease processes, with malarial infections being more 
severe in patients infected with HIV and HIV replication increasing in malaria 
infection. 
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Young children aged 6 months to 3 years who live in endemic areas are at an 
increased risk of death due to malaria. Travelers without immunity are at an 
increased mortality risk, regardless of age.  
 
 
Mortality 
 
Internationally, malaria is responsible for approximately 1-3 million deaths per year. 
Of these deaths, the overwhelming majority are in children aged 5 years or younger, 
and 80-90% of the deaths each year are in rural sub-Saharan Africa.
 
Malaria is the 
world’s fourth leading cause of death in children younger than age 5 years.  
 
Malaria is preventable and treatable. However, the lack of prevention and treatment 
due to poverty, war, and other economic and social instabilities in endemic areas 
results in millions of deaths each year.  
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MALARIAL LIFE CYCLE 
 
Fig. No.4 
 
Causes, incidence, and risk factors: 
Malaria is caused by a parasite that is passed from one human to another by the bite 
of infected Anopheles mosquitoes. After infection, the parasites [called sporozoites] 
travel through the bloodstream to the liver, where they mature and release another 
form, the merozoites. The parasites enter the bloodstream and infect red blood cells. 
The parasites multiply inside the red blood cells, which then break open within 48 to 
72 hours, infecting more red blood cells. The first symptoms usually occur 10 days 
to 4 weeks after infection, though they can appear as early as 8 days or as long as a 
year after infection. The symptoms occur in cycles of 48 to 72 hours. 
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Most symptoms are caused by:
3
 
 The release of merozoites into the bloodstream 
 Anemia resulting from the destruction of the red blood cells 
 Large amounts of free hemoglobin being released into circulation after red 
blood cells break open 
 Malaria can also be transmitted from a mother to her unborn baby 
[congenitally] and by blood transfusions. Malaria can be carried by 
mosquitoes in temperate climates, but the parasite disappears over the winter. 
 The disease is a major health problem in much of the tropics and subtropics. 
The CDC estimates that there are 300-500 million cases of malaria each year 
and more than 1 million people die from it. It presents a major disease hazard 
for travelers to warm climates. 
 In some areas of the world, mosquitoes that carry malaria have developed 
resistance to insecticides. In addition, the parasites have developed resistance 
to some antibiotics. These conditions have led to difficulty in controlling 
both the rate of infection and spread of this disease. 
 There are four types of common malaria parasites. Recently, a fifth type, 
Plasmodium knowlesi, has been causing malaria in Malaysia and areas of 
southeast Asia. Another type, falciparum malaria, affects more red blood 
cells than the other types and is much more serious. It can be fatal within a 
few hours of the first symptoms. 
Symptoms: 
 Anaemia 
 Bloody stools 
 Chills 
 Coma 
 Convulsion 
 Fever 
 Headache 
 Jaundice 
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 Muscle pain 
 Nausea 
 Sweating 
 Vomiting 
Signs and tests: 
During a physical examination, the doctor may find an enlarged liver or enlarged 
spleen. Malaria blood smears taken at 6 to 12 hour intervals confirm the diagnosis. 
A complete blood count [CBC] will identify anemia if it is present. 
Treatment: 
Malaria, especially Falciparum malaria, is a medical emergency that requires a 
hospital stay. Chloroquine is often used as an anti-malarial medication. However, 
chloroquine-resistant infections are common in some parts of the world. 
Possible treatments for chloroquine-resistant infections include: 
 The combination of quinidine or quinine plus doxycycline, tetracycline, or 
clindamycin 
 Atovaquone plus proguanil [Malarone] 
 Mefloquine or artesunate 
 The combination of pyrimethamine and sulfadoxine [Fansidar] 
 The choice of medication depends in part on where you were when you were 
infected. 
 Medical care, including fluids through a vein [IV] and other medications and 
breathing [respiratory] support may be needed. 
Expectations: [prognosis] 
The outcome is expected to be good in most cases of malaria with treatment, but 
poor in P falciparum infection with complications. 
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Complications: 
Most complications are caused by P falciparum. One of them is cerebral malaria, 
defined as coma, altered mental status, or multiple seizures with P falciparum in the 
blood. Cerebral malaria is the most common cause of death in patients with malaria. 
If untreated, this complication is lethal. Even with treatment, 15% of children and 
20% of adults who develop cerebral malaria die. The symptoms of cerebral malaria 
are similar to those of toxic encephalopathy. Other complications of P falciparum 
infection include the following:  
 Seizures - Secondary to either hypoglycemia or cerebral malaria 
 Renal failure - As many as 30% of nonimmune adults infected with P 
falciparum suffer acute renal failure 
 Hypoglycemia 
 Hemoglobinuria [blackwater fever] - Blackwater fever is the passage of dark 
urine, described as Madeira wine colored; hemolysis, hemoglobinemia, and 
the subsequent hemoglobinuria and hemozoinuria cause this condition  
 Noncardiogenic pulmonary edema - This affliction is most common in 
pregnant women and results in death in 80% of patients 
 Profound hypoglycemia - Hypoglycemia often occurs in young children and 
pregnant women; it often is difficult to diagnose because adrenergic signs are 
not always present and because stupor already may have occurred in the 
patient  
 Lactic acidosis - This occurs when the microvasculature becomes clogged 
with P falciparum; if the venous lactate level reaches 45 mg/dL, a poor 
prognosis is very likely 
 Hemolysis resulting in severe anemia and jaundice 
 Bleeding [coagulopathy] 
 Brain infection [cerebritis] 
 Liver failure 
 Rupture of the spleen leading to massive internal bleeding [hemorrhage]. 
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Prevention: 
Most people who live in areas where malaria is common have gotten some immunity 
to the disease. Visitors will not have immunity, and should take preventive 
medications. 
It is important to see your health care provider well before your trip, because 
treatment may need to begin as long as 2 weeks before travel to the area, and 
continue for a month after you leave the area. In 2006, the CDC reported that most 
travelers from the U.S. who contracted malaria failed to take the right precautions. 
The types of anti-malarial medications prescribed will depend on the area you visit. 
According to the CDC, travelers to South America, Africa, the Indian subcontinent, 
Asia, and the South Pacific should take one of the following drugs: mefloquine, 
doxycycline, chloroquine, hydroxychloroquine, or Malarone. Even pregnant women 
should take preventive medications because the risk to the fetus from the medication 
is less than the risk of catching this infection. 
People who are taking anti-malarial medications may still become infected. Avoid 
mosquito bites by wearing protective clothing over the arms and legs, using screens 
on windows, and using insect repellent. 
Chloroquine has been the drug of choice for protecting against malaria. But because 
of resistance, it is now only suggested for use in areas where Plasmodium vivax, P. 
oval, and P. malariae are present. Falciparum malaria is becoming increasingly 
resistant to anti-malarial medications. 
For travelers going to areas where Falciparum malaria is known to occur, there are 
several options for malaria prevention, including mefloquine, atovaquone/proguanil 
[Malarone], and doxycycline. 
 
 
 
 
 
 49 
 
ANTIMALARIAL DRUGS 
Antimalarial drugs 
        These are drugs used for prophylaxis, treatment and prevention of relapses of 
malaria.  It is endemic in most parts of India and other tropical countries. It is one of 
the major health problems.  
As per latest WHO estimates there are 300-500 million new clinical cases globally 
and >1 million deaths occur due to malaria each year, 90% of which are in Africa.  
In India the National Malaria Eradication Programme [NMEP], started in 1958, 
achieved near complete disappearance of the disease in 1960s.  However, due to the 
development of insecticide resistance among mosquitoes and other factors, it staged 
a comeback in the mid 1970s [6.47 million cases in 1976], and continues to prevail 
in endemic/ subendemic proportions in different areas.  
Conceding that eradication of malaria is not possible, NMEP was renamed National 
Antimalaria Programme [NAMP]. 
Its scope has now been widened to include other vector borne diseases, and it is 
called “National Vector borne diseases control programme” [NVBDCP].  
For the year 2005, the NVBDCP has reported 1.8 million slides proven malaria 
cases in India, out of which ≈44% were falciparum malaria with 963 deaths.  
The WHO estimates that actual number of malaria cases in India is 6 times more, i.e. 
~12 million. 
History of Antimalarial drugs:  
 The bark of cinchona introduced in early 17th century as a cure for fevers.  
 Later Quinine, isolated from cinchona bark in 1820 and used till 1942.    
 Mepacrine was produced in germany in 1926 and extensively field tested by 
the Allies during world war 2. 
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 Chloroquine was produced in USA soon after as a less toxic alternative to 
mepacrine. 
 Proguanil was introduced in1945 by the British as a well tolerated clinical 
alternative. 
 None of the above drugs were found to be capable of preventing relapses in 
vivax malaria. 
 Pamaquine tested in 1920s and primaquine emerged as the most desirable 
drug. No attention paid to these drugs because of poor schizontocide action. 
 Pyrimethamine was produced in 1951 under a planned post-war research 
programme for antimalarial drugs. 
 The most important additions of the recent years  are Mefloquine, 
ARTEMISININ and its derivatives/ congeners, pyronaridine and few other 
synthetic compounds for resistant falciparum malaria.  
Classification of antimalarial drugs: 
 4 – Aminoquinolines  - Chloroquine, Amodiaquine, Piperaquine. 
 Quinoline – methanol - Mefloquine. 
 Cinchona alkaloid - Quinine, Quinidine. 
 Biguanides - Proguanil, Chlorproguanil. 
 Diaminopyrimidines - Pyrimethamine. 
 8 – aminoquinoline - Primaquine, Bulaquine. 
 Sulfonamides and Sulfone - Sulfadoxine, Sulfamethopyrazine, Dapsone. 
 Tetracyclines - Tetracycline, Doxycycline. 
 Sesquiterpine lactones - Artesunate, Artemether, Arteether. 
 Amino alcohols - Halofantrine, Lumefantrine. 
 Mannich base - Pyronaridine. 
 Naphthoquinone - Atovaquone.  
The use of a single first-line therapy effective against both P. vivax and P. 
falciparum would be ideal in view of the frequent co-endemicity of the two species 
and the increasing resistance of parasites to chloroquine.  
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The widespread adoption of artemisinin-based combination therapies [ACTs] as 
highly effective first-line therapy for P.falciparum has prompted a closer 
examination of their role in the management of P.vivax malaria.  
This project work considers the available evidence relating to the potential role of 
artemether-lumefantrine [AL], the most widely used ACT worldwide, in the 
management of vivax malaria.  P. vivax Life Cycle and Implications for the 
Evaluation of Efficacy of Antimalarials 
In contrast to P. falciparum, P. vivax forms hypnozoites that can remain dormant in 
the parenchymal cells of the host liver following an acute infection. After an interval 
of time, which varies in duration depending on the geographical area , the 
hypnozoites can mature into hepatic schizonts that rupture to release merozoites 
capable of infecting erythrocytes and inducing a spontaneous relapse [Figure 1]. 
Clinically, relapses present as a new malaria episode, indistinguishable from a new 
infection. 
P. vivax life cycle and sites of action for different Antimalarials. 
 
Fig.No.5 
Thus, in P. vivax infections, the eradication of blood schizonts is not sufficient to 
control the disease, and an effective treatment requires killing the hypnozoites 
[“radical cure”] to prevent future relapses. 
 Chloroquine, an inexpensive and effective treatment for vivax malaria in most areas 
of the world has been the mainstay first-line therapy for this species for the past 
seven decades.  
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It is still WHO's recommended drug for vivax, but needs to be combined with 
primaquine, currently the only approved drug capable of achieving radical cure of 
hypnozoites. WHO guidelines state that primaquine needs to be administered daily 
for 14 d to achieve this purpose, although the efficacy of shorter courses is being 
investigated.  
Chloroquine achieves parasitological cure at day 28 in more than 90% of 
chloroquine-sensitive P. vivax infections, but in many areas of the world, significant 
levels of resistance to this drug in P. vivax have been documented, notably in 
Indonesia [<50% probability of therapeutic success] and to a lesser extent in India, 
Myanmar, Turkey, the Brazilian Amazon, and Colombia.  
Worryingly, there is also growing evidence of clinical resistance of vivax to 
Chloroquine in Africa.  
Emergence of resistance to Chloroquine, particularly in view of the potentially 
serious consequences of vivax infection, adds a further urgency to providing 
effective therapy. 
The possibility of relapse brings about uncertainty when assessing the efficacy of 
Antimalarial drugs that have an effect on asexual stages of the life cycle but not on 
the dormant liver forms.  
Thus, patients correctly treated with an Antimalarial with no Antihypnozoite activity 
may present with recurrent post-treatment parasitemia that can derive from one of 
three sources: 
 [1] Reappearing parasites as a result of the incomplete clearance of the original 
infection [recrudescence], often the consequence of ineffective or incomplete 
treatment,  
  [2] Generation of de novo parasitemia from the liver reservoirs [relapse], or  
 [3] Parasites ensuing from a new and independent infection [new infection].  
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Parasites in recrudescent or relapsing infections may be genetically identical to the 
original infection and thus impossible to differentiate with current technology. 
 Some reports state that over half of the relapsing parasites may be genetically 
different from the preceding documented infection, but this may be explained by 
older heterologous hypnozoites becoming reactivated. 
A new infection arising from the bite of an infected vector, however, may differ 
from the original infecting parasite such that they can be distinguished from one 
another by PCR molecular techniques. 
 A pragmatic solution to this investigative hurdle has been adopted whereby any new 
parasitemia appearing before day 16 is by convention directly classified as 
recrudescence [i.e., treatment failure] because of the unlikelihood of the infection 
being a relapse within such a short space of time, and because this is the minimum 
incubation period for a new infection to appear in peripheral blood. Reappearance of 
parasites after day 16 cannot be assumed to be recrudescence. 
Possible sources of residual blood parasitemia after initial treatment and possible 
genetic similarity or dissimiliarity. 
 
 
 
 
 
 
 
 
 
 54 
 
ACTs in Vivax Malaria 
  
Fig. No.6 
ACTs are highly effective against uncomplicated P. falciparum malaria and are now 
recommended as first-line therapy, having been adopted in most countries where P. 
falciparum is endemic. 
 Most ACTs show high and similar efficacy against the blood stages of P. vivax, but 
none is active against the hepatic P. vivax hypnozoites responsible for relapse.  
Therefore, in order to achieve radical cure, similar to Chloroquine treatment, ACT 
treatment must be complemented with a full course of primaquine. 
Where both P. vivax and P. falciparum species are prevalent and ACTs have been 
adopted as first-line therapy for P. falciparum, use of a unified first-line therapy 
based on ACTs would simplify treatment procurement, distribution, and 
management, offering interesting logistical benefits. 
 ACT therapy for both types of infections would also avoid the problem of P. 
falciparum being mistakenly diagnosed as P. vivax and inadequately treated with 
Chloroquine in the many regions where diagnosis is based on clinical symptoms 
alone.  
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In areas of Chloroquine-resistant P. vivax, and where ACTs have already been 
adopted for the treatment of P. falciparum malaria, ACTs could also be used for the 
treatment of vivax, provided they are complemented with the standard Primaquine 
course.  
Indeed, at least four countries have now adopted a unified first-line therapy based on 
ACTs: the Solomon Islands, Vanuatu, and Papua New Guinea deploy AL, while 
Indonesia deploys Dihydroartemisinin-piperaquine [DHA-PQP] in Papua. 
 
COMBINATION THERAPY
2,5
 
Combination therapy or polytherapy is the use of more than one medication or other 
therapy. In contrast, monotherapy is any therapy which is taken by itself. 
Definition: 
Combination drug therapy is defined as the use of 2 or more pharmacologic agents 
administered separately or in a fixed-dose combination of 2 or more active 
ingredients in a single-dosage formulation. Combination therapy is frequently 
prescribed by physicians to treat and manage a plethora of medical conditions; 
Most often, these terms refer to the simultaneous administration of two or more 
medications to treat a single disease. However, the expression is also used when 
other types of therapy are used at the same time, such as the combination of 
medications and talk therapy to treat depression. 
Combination therapy may be achieved by giving separate drugs, or, where available, 
by giving combination drugs, which are dosage forms that contain more than one 
active ingredient. 
Polypharmacy is the use of multiple medications to treat multiple, separate diseases. 
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Uses for combination therapy: 
Conditions treated with combination therapy include tuberculosis, leprosy, cancer, 
malaria, and HIV/AIDS. One major benefit of combination therapies is that they 
reduce development of drug resistance, since a pathogen or tumor is less likely to 
have resistance to multiple drugs simultaneously. Artemisinin-based monotherapies 
for malaria are explicitly discouraged to avoid the problem of developing resistance 
to the newer treatment. 
Combination therapy may seem costlier than monotherapy in the short term, but 
when used appropriately, it causes significant savings: lower treatment failure rate, 
lower case-fatality ratios, slower development of resistance and consequently, less 
money needed for the development of new drugs. 
 
Uses for monotherapy: 
Monotherapy can be applied to any therapeutic approach, but it is most commonly 
used to describe the use of a single medication. Normally, monotherapy is selected 
because a single medication is adequate to treat the medical condition. However, 
monotherapies may also be used because of unwanted side effects or dangerous drug 
interactions. 
Combination therapy: 
Following increased resistance of malaria parasites to conventional drugs in the 
malarial regions of the world, the WHO is promoting artemisinin-based combination 
therapy (ACT) for treating uncomplicated malaria. The objective of this report is to 
review the available scientific information on the efficacy, safety, resistance and 
policy implementation of ACT as it relates to sub-Saharan Africa since the Abuja 
2000 Roll Back Malaria initiative. To achieve this, a Medline search was performed 
to identify scientific publications relevant to the review. The data reviewed indicated 
that ACT proved very effective in the treatment of uncomplicated Plasmodium 
falciparum malaria in the region. ACT was shown to be effective, safe and tolerable 
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and no resistance has been detected so far. However, the major challenges to its 
widespread use in the region include its high cost, low drug quality and poor 
healthcare delivery systems, among others. It is absolutely imperative for sub-
Saharan African countries to establish an effective national antimalarial drug policy 
which will provide safe, effective, high-quality, accessible and affordable 
antimalarial drugs such as ACT to the populations at risk of malaria but, at the same 
time, promote rational drug use in order to delay or prevent the development of 
antimalarial drug resistance.  
Cellular pathways operate more like webs than superhighways. There are multiple 
redundancies, or alternate routes, that may be activated in response to the inhibition 
of a pathway. This redundancy promotes the emergence of resistant cells or 
organisms under the selective pressure of a targeted agent, resulting in drug 
resistance and clinical relapse. For this reason, combination therapies are often 
needed to effectively treat many tumors and infectious diseases. 
 
Concern has been expressed that the policies of the Food and Drug Administration 
(FDA) on the development of combination therapies, which heretofore have focused 
primarily on fixed-dose combinations (i.e., combined in the same tablet or vial) of 
already-marketed drugs, are a barrier to the development of novel combination 
regimens using targeted therapies.1 FDA regulations for fixed-dose combinations 
require demonstration of the contribution of each component of the combination to 
the treatment effect. Often, a large clinical trial, using a multigroup factorial design 
to demonstrate that the combination is superior to each of the individual components 
alone, is needed to meet this requirement. For example, a factorial study for a two-
drug combination could have four groups so that the combination can be compared 
with each of the individual components alone, as well as with either the standard of 
care or placebo. 
The development of effective therapies for serious diseases is a primary FDA 
objective. The agency recognizes the therapeutic potential of innovative 
combination therapies and is committed to fostering their development. The FDA 
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also recognizes the uncertainties inherent in combination development programs and 
is equally committed to effectively managing those risks. 
 
Conclusion: 
Combination drug therapy is often necessary for the management and treatment of 
various chronic medical conditions, including CVD, hypertension, diabetes and 
malaria. 
 As more fixed-dose combination formulations become available, they should be 
considered for use with the aims of improving patient adherence, simplifying drug 
regimens, and optimizing care.  
Patients should be encouraged to maintain routine visits with their primary health 
care provider so they can be properly monitored. 
 Although studies have shown that combination drug therapy is often beneficial for 
the treatment of many patients, pharmacists are vital to ensuring that these agents are 
used appropriately by screening for potential drug–drug interactions, 
contraindications such as hepatic or renal problems, and unnecessary drug use.  
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2. LITERATURE REVIEW 
1] David Joseph Diemert et al,
36
 The George Washington University Medical 
Center, United States of America December 27, 2011 has done research in the Use of 
Artemether-Lumefantrine for the Treatment of Uncomplicated Plasmodium vivax 
Malaria. A unified treatment strategy for both falciparum and vivax infections using 
ACTs that have already been deployed in many malaria-endemic areas of the world 
would offer important logistical and cost advantages, especially in areas of high 
chloroquine resistance or where parasitological diagnosis remains challenging. The 
efficacy of AL against the blood stages of P. vivax seems clear, showing rapid 
parasite and fever clearance. 
 2] Michael Makanga, et al,
37
 12 October 2009, researched in the clinical efficacy 
of artemether / lumefantrine [Coartem®], Current World Health Organization 
[WHO] guidelines for the treatment of uncomplicated falciparum malaria 
recommend the use of artemisinin-based combination therapy [ACT]. 
Artemether/lumefantrine is an ACT prequalified by the WHO for efficacy, safety and 
quality, approved by Swissmedic in December 2008 and recently approved by the 
USA FDA. Coartem® is a fixed-dose combination of artemether and lumefantrine. 
Its two components have different modes of action that provide synergistic anti-
malarial activity. It is indicated for the treatment of infants, children and adults with 
acute, uncomplicated infection due to Plasmodium falciparum or mixed infections 
including P. falciparum. The efficacy of the six-dose regimen of 
artemether/lumefantrine has been confirmed in many different patient populations 
around the world, consistently achieving 28-day PCR [polymerase chain reaction]-
corrected cure rates of >95% in the evaluable population, rapidly clearing 
parasitaemia and fever, and demonstrating a significant gametocidal effect, even in 
areas of widespread parasite resistance to other antimalarials.  
 3] J.Sunil, et.al,
38
vol.2,4 2010, IJPPS, has developed HPLC method development 
and validation for simultaneous estimation of Artemether and Lumefantrine in 
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pharmaceutical dosage forms. A simple and precise HPLC method was developed 
for the estimation of artemether and lumifantrine in pure and pharmaceutical dosage 
forms. The quantification was carried out using symmetry C 18, 250 × 4.6 mm , i.d , 
5µm partical size in isocratic mode , with mobile phase compressing of buffer and 
acetonitrile in the ratio of 40:60 [v/v] PH 3 ±0.5. Flow rate was 1.5 m/min and 
detection carried out by uv detector dual 210 and 303 nm. The retention times were 
13.887 and 7.218 mins for artemether and lumefantrine, respectively. The percentage 
recovery was found to be 98.87 and 99.78% for artemether  and lumefantrine, 
respectively.  
4] Naawa Sipilanyambe et al,
39
 29 January 2008, A decision was made to change 
national drug policy to artemether-lumefantrine [AL] in the first quarter of 2002, 
with a formal announcement made in October 2002. During this period, efforts were 
undertaken to identify funding for the procurement of AL and to develop new 
malaria treatment guidelines, training materials, and plans for implementation of the 
policy. In order to avoid a delay in implementation, the policy change decision 
required a formal adoption within existing legislation. Starting with donated drug, a 
phased deployment of AL began in January 2003 with initial use in seven districts 
followed by scaling up to 28 districts in the second half of 2003 and then to all 72 
districts countrywide in early 2004.  
5] Abdulla et al,
40
 licensee BioMed Central Ltd. 3 September 2010, developed a 
Early clinical development of artemether-lumefantrine dispersible tablet: palatability 
of three flavours and bioavailability in healthy subjects.  Efforts to ease 
administration and enhance acceptability of the oral anti-malarial artemether-
lumefantrine [A-L] crushed tablet to infants and children triggered the development 
of a novel dispersible tablet of A-L. During early development of this new 
formulation, two studies were performed in healthy subjects, one to evaluate the 
palatability of three flavours of A-L, and a second one to compare the bioavailability 
of active principles between the dispersible tablet and the tablet [administered 
crushed and intact].  
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6] P Umapathi et al,
41
 oct 2011,tjpr has reasearched in development  and validation 
of a dissolution test method for Artemether  and Lumefantrine in tablets. A  single 
dilution method for evaluating the invitro release of artemether and Lumefantrine 
from tablets was developed and evaluated. The dissolution medium of 1000 ml of 
2% w/v of Myrj 52 in 0.0052M Hcl per vessel with the paddle rotation of 100 to 120 
per minute. The dissolution samples were analysed using a Water HPLC system C-
18. The mobile phase was a mixture of 20 volumes of 0.5 %v/v/of triethylamine in 
water [PH 3.0 with orthophosphoric acid] and 80 volumes of acetonitrile. The 
detection wavelength was set at 216 nm and 100 µl of each sample was injected. The 
dissolution test provided sink conditions for Artemether and Lumefantrine and was 
able to discriminate between tablet formulations of different hardness and direct 
composition. 
7] Pauline Byakika et al,
42
 14 February 2011, has researched in  Artemether-
Lumefantrine Combination Therapy for Treatment of Uncomplicated Malaria: The 
Potential for Complex Interactions with Antiretroviral Drugs in HIV-Infected 
Individuals. Treatment of malaria in HIV-infected individuals receiving antiretroviral 
therapy [ART] poses significant challenges. Artemether-lumefantrine [AL] is one of 
the artemisisnin-based combination therapies recommended for treatment of malaria. 
The drug combination is highly efficacious against sensitive and multidrug resistant 
falciparum malaria. Both artemether and lumefantrine are metabolized by hepatic 
cytochrome P450 [CYP450] enzymes which metabolize the protease inhibitors [PIs] 
and nonnucleoside reverse transcriptase inhibitors [NNRTIs] used for HIV treatment. 
Coadministration of NNRTIs and PIs with AL could potentially cause complex 
pharmacokinetic drug interactions. NNRTI by inducing CYP450 3A4 enzyme and 
PIs by inhibiting CYP450 3A4 enzymes could influence both artemether and 
lumefantrine concentrations and their active metabolites dihydroartemisinin and 
desbutyl-lumefantrine, predisposing patients to poor treatment response, toxicity, and 
risk for development of resistance. There are scanty data on these interactions and 
their consequences. Pharmacokinetic studies to evaluate these interactions in the 
target populations are urgently needed. 
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8] Aika AA Omari et al, 2009
43
 The Cochrane Collaboration. Published by 
JohnWiley & Sons, Ltd. Artemether-lumefantrine [six-dose regimen] for treating 
uncomplicated falciparum malaria.Malaria is a parasitic disease, spread by 
mosquitoes. It affects millions of people worldwide, and causes significant illness 
and mortality.  Uncomplicated malaria presents with symptoms such as fever, 
headache, muscle pain, and vomiting. The parasite has become resistant to a number 
of previously effective drugs, and so combinations of drugs are used to try increase 
cure and to prevent further resistance.Artemether-lumefantrine is one such drug 
combination. This review of trials showed that the six-dose regimen of artemether-
lumefantrine was associated with high cure rates and was more effective that most 
other drug combinations used for uncomplicated malaria. Further research is needed 
to properly assess adverse outcomes. The fixed-dose combination of artemether-
lumefantrine, called co-artemether, contains 20mg of artemether and 120mg of 
lumefantrine [previously called benflumetol]. It was initially developed by scientists 
at the Academy ofMilitaryMedical Sciences in China before the pharmaceutical 
company Novartis [Switzerland] became a partner and was licensed to market it as 
Coartem® or Riamet. This oral preparation has been designed for use against 
chloroquine-resistant falciparum malaria.  
9] Naawa Sipilanyambe
 
et al,
44
 Malaria Journal 2008 biomed, Convincing 
evidence of the failing efficacy of chloroquine resulted in the initiation of a process 
that eventually led to the development and implementation of a new national drug 
policy based on artemisinin-based combination therapy [ACT]. the transition to 
effective malaria case-management strategies including efficacious ACT is a 
fundamental cornerstone for malaria control. These policy changes are not without 
difficulties and demand a sustained international financing strategy for them to 
succeed. The Zambian experience demonstrates the need for a harmonized national 
consensus among many stakeholders and a political commitment to ensure that new 
policies are translated into practice quickly. To guarantee effective policies become 
ssa health system and not a drug issue. 
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10] Billy E Ngasala et al,
45
 Effectiveness of artemether-lumefantrine provided by 
community health workers in under-five children with uncomplicated malaria in 
rural Tanzania: an open label prospective study.An open label, single arm 
prospective study was conducted in two rural villages with high malaria transmission 
in Kibaha District, Tanzania. Children presenting to CHWs with uncomplicated fever 
and a positive rapid malaria diagnostic test [RDT] were provisionally enrolled and 
provided AL for unsupervised treatment at home. Patients with microscopy 
confirmed P. falciparum parasitaemia were definitely enrolled and reviewed weekly 
by the CHWs during 42 days. Primary outcome measure was PCR corrected 
parasitological cure rate by day 42, as estimated by Kaplan-Meier survival analysis. 
This trial is registered with ClinicalTrials.gov, number NCT00454961. Provision of 
AL by CHWs for unsupervised malaria treatment at home was highly effective, 
which provides evidence base for scaling-up implementation of HMM with AL in 
Tanzania. 
11] Rod Ibara-Okabande et al,
46
 Malaria Journal 2012 Reduction of multiplicity of 
infections but no change in msp2 genetic diversity in Plasmodium falciparum isolates 
from Congolese children after introduction of artemisinin-combination therapy. This 
study shows that the introduction of ACT in the Republic of Congo has reduced the 
multiplicity of infection but not the genetic diversity of P. falciparum isolates from 
children living in Southern districts of Brazzaville. It also points out that children 
exposed to the same malaria transmission and socio-economic conditions might have 
different susceptibility to malaria infections. The two groups described here are 
important for designing additional studies to investigate human and parasite genetic 
factors that may be involved in the susceptibility/resistance to malaria in this area. 
12] Abdallah et al,
47
 Malaria Journal 2012, The spread of multidrug-resistant 
Plasmodium falciparum malaria in Sudan [10,11] has led to adoption of artemisinin-
based combination therapy [ACT], with artesunate–sulphadoxine–pyrimethamine 
[AS–SP] and artemether–lumefantrine [AL] becoming the recommended first- and 
secondline treatments for uncomplicated P. falciparum malaria,  respectively. ACT is 
highly effective against uncomplicated P. falciparum malaria and, as a consequence 
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of high levels of chloroquine resistance, is now widely adopted as the first-line 
therapy in most malaria endemic countries, including Sudan [10]. Indeed, some 
countries such as Papua New Guinea and Indonesia have adopted ACT as the first-
line therapy for P. vivax and P. falciparum malaria [16]. A policy whereby use of a 
unified first-line therapy based on ACT was implemented could have great public 
health value in that it would simplify treatment, management and logistics of malaria 
disease control. It should be mentioned that chloroquine is no longer registered or 
available for use in Sudan, so as to avoid the problem of P. falciparum infection 
being treated with chloroquine. 
13] Vaughan-Williams et al.
48
 Malaria Journal 2012, Assessment of the therapeutic 
efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium 
falciparum malaria in northern KwaZulu-Natal: an observational cohort study. 
artemether-lumefantrine has been used as first-line treatment for uncomplicated 
Plasmodium falciparum malaria in northern KwaZulu-Natal since 2001, its efficacy 
has not been assessed since 2002. The objectives of this study were to quantify the 
proportion of patients treated for uncomplicated P. falciparum malaria with 
artemether-lumefantrine who failed treatment after 28 days, and to determine the 
prevalence of molecular markers associated with artemether-lumefantrine and 
chloroquine resistance. An observational cohort of 49 symptomatic patients, 
diagnosed with uncomplicated P. falciparum malaria by rapid diagnostic test, had 
blood taken for malaria blood films and P. falciparum DNA polymerase chain 
reaction [PCR]. Following diagnosis, patients were treated with artemether-
lumefantrine [CoartemW] and invited to return to the health facility after 28 days for 
repeat blood film and PCR. All PCR P. falciparum positive samples were analysed 
for molecular markers of lumefantrine and chloroquine resistance. 
14] Faye et al. Malaria Journal 2012,
49
 Multicentre study evaluating the non-
inferiority of the new paediatric formulation of artesunate/ amodiaquine versus 
artemether/lumefantrine for the management of uncomplicated Plasmodium 
falciparum malaria in children in Cameroon, Ivory Coast and Senegal. to evaluate the 
non-inferiority of the new paediatric formulation of artesunate/amodiaquine 
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[AS+AQ][Camoquin-Plus PaediatricW] in suspension form versus 
artemether/lumefantrine [AL][CoartemW] in the management of African children 
with uncomplicated falciparum malaria. It was an open randomized trial including 
children aged between 7 months and 7 years. The endpoints were Adequate Clinical 
and Parasitological Response [ACPR] at day 28, the clinical and biological 
tolerability. Statistical analyses were done in Intention to Treat [ITT] and in Per 
protocol [PP]. At the end of the study 481 patients were enrolled in the three 
countries [249 in the AS+AQ arm and 232 in the AL arm]. ACRP in ITT after PCR 
correction did not show any statistical difference between the two groups with 97.6% 
for AS+AQ versus 94.8% for AL. In the PP analysis, the corrected ACRP were 
respectively 98.7% and 96.9% for the two regimens. The clinical tolerance was good 
without significant difference. Anaemia was significantly higher at D7 in the two 
groups compared to D0.This study demonstrates the non-inferiority of AS+AQ 
versus AL, its efficacy and tolerance in the management of uncomplicated 
Plasmodium falciparum malaria in African children. 
15] Tajeldin M Abdallah et al,
50
 Malaria Journal 2012, Efficacy of artemether-
lumefantrine as atreatment for uncomplicated Plasmodium vivaxmalaria in eastern 
Sudan. Artemisinin-based combination therapy [ACT] is the treatment of choice for 
uncomplicated Plasmodium falciparum malaria in most areas of the world, where 
malaria is endemic, including Sudan. However, few published data are available on 
the use of ACT for treatment of P. vivax malaria. This study was conducted at a 
health centre in Kassala, eastern Sudan, from October to December 2011. Patients 
with uncomplicated P. vivax malaria received artemether-lumefantrine [AL] tablets 
[containing 20mg artemether and 120 mg lumefantrine] and were monitored for 28 
days. Out of the 43 cases enrolled in this study, 38 completed the 28-day follow-up. 
Their mean age was 25.1 years [SD: 1.5]. On day 3 following AL treatment, all of 
the patients were afebrile and aparasitaemic. By day 28, all 38 patients exhibited 
adequate clinical and parasitological responses to AL treatment. The cure rate was 
100% and 88.4% for the per protocol analysis andfor the intention to treat analysis, 
respectively. Mild adverse effects [nausea, vomiting, abdominal pain, dizziness 
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and/or rash] that resolved spontaneously were observed in four [10.5%] of the 
patients. AL combination therapy was fully effective for treatment of P. vivax 
malaria in the study in eastern Sudan. 
16] Shretta and Yadav Malaria Journal 2012,
51
 Stabilizing supply of artemisinin 
and artemisinin-based combination therapy in an era of wide-spread scale-up. The 
global demand for artemisinin-based combination therapy [ACT] has grown sharply 
since its recommendation by the World Health Organization in 2002. However, a 
combination of financing and programmatic uncertainties, limited suppliers of 
finished products, information opacity across the different tiers in the supply chain, 
and widespread fluctuations in raw material prices have together contributed to a 
market fraught with demand and supply uncertainties and price volatility. Various 
short-term solutions have been deployed to alleviate supply shortages caused by 
these challenges; however, new mechanisms are required to build resilience into the 
supply chain. This review concludes that a mix of strategies is required to stabilize 
the artemisinin and ACT market. First, better and more effective pooling of demand 
and supply risks and better contracting to allow risk sharing among the stakeholders 
are needed. Physical and financial buffer stocks will enable better matching of 
demand and supply in the short and medium term. Secondly, physical buffers will 
allow stable supplies when there are procurement and supply management challenges 
while financial buffer funds will address issues around funding disruptions. 
Finally, in the medium to long term, significant investments in country level system 
strengthening will be required to minimize national level demand uncertainties. In 
addition a voluntary standard for extractors to ensure appropriate purchasing and 
sales practices as well as minimum quality and ethical standards could help stabilize 
the artemisinin market in the long term. 
17] Abuaku et al.
52
 Malaria Journal 2012, Therapeutic efficacy of artemether-
lumefantrine combination in the treatment of uncomplicated malaria among children 
under five years of age in three ecological zones in Ghana. AL remains efficacious in 
Ghana with significant ecologic zonal differences. The  savannah zone may be a 
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potential zone for any emergence of resistant alleles as a result of the slower parasite 
clearance observed in the zone. Pharmacokinetic studies will be useful in future anti-
malarial drug resistance surveillance activities in Ghana to better describe treatment 
failures. Ghana’s policy of multiple first-line therapy is in the right direction, and 
needs to be supported by all stakeholders as it delays the emergence and slows 
spread of drug resistance [28,29]. Furthermore, the WHO criteria for ETF may need 
to be reviewed following the observation that all 5 children classified as ETF on the 
basis of parasite count on day-2 being greater than parasite count on day-0 cleared all 
parasites on day-3, without any rescue treatment, and remained aparasitaemic during 
the follow-up period. 
18] Kayentao et al,
53
 Malaria Journal 2012, Artemisinin-based combination therapy 
[ACT] is the mainstay of global efforts for treatment of Plasmodium falciparum 
malaria, but decline in its efficacy is the most important obstacle towards malaria 
control and elimination. Therefore, the present molecular analysis provides 
information on putative mutations associated with artemisinin resistance in P. 
falciparum clinical population unexposed and exposed to artesunate 4 years after 
adoption of ACT as the first-line anti-malarial therapy in Iran. Molecular assessment 
of atpase6 mutations associated with artemisinin resistance among unexposed and 
exposed Plasmodium falciparum clinical isolates to artemisinin-based combination 
therapy. Results: Neither the pfatpase6 L263E nor the A623E mutation was detected 
among all examined isolates. The E431K mutation was found in 23% of the analysed 
samples unexposed to ACT; however, it was detected in 17.8% [34/191] of P. 
falciparum isolates exposed to artesunate after 2007. High frequency of this single 
nucleotide polymorphisms [SNP] [overall 18.6%] among both examined groups [X2 
test, P>0.05] indicated that this SNP should be considered as an unrelated mutation 
to artemisinin resistance. In contrast, S769N mutation was not detected in unexposed 
isolates; however, it was found in 2.6% [5/191], four years after introduction of ACT 
in this malaria setting. Also, detected SNPs were not significantly frequent in both 
unexposed and exposed examined isolates [X2 test, P> 0.05]. Investigation in the 
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copy number of pfatpase6 gene revealed a similar number of copy [n = 1] as in an 
isolate sensitive to artemisinin. 
19] Eibach et al.
54
 Malaria Journal 2012, Therapeutic efficacy of artemether-
lumefantrine for Plasmodium vivax infections in a prospective study in Guyana. A 
therapeutic efficacy study was conducted using artemether-lumefantrine + 
primaquine against P. vivax to evaluate a treatment alternative for chloroquine. 
Methods: From 2009 to 2010, a non-controlled study in two hospitals in Guyana was 
conducted. A total 61 patients with P. vivax infection were treated with artemether-
lumefantrine as a six-dose regimen twice a day for three days with additional 0.25 
mg/kg/d primaquine at day 0 for 14 days. Clinical and parasitological parameters 
were followed on days 0,1,2,3,7,14 and 28 in agreement with WHO guidelines. 
Plasmodium vivax DNA from eight patients was analysed for pvmdr1, molecular 
marker of resistance. Results: Artemether-lumefantrine cleared 100% of parasites on 
day 1, but two patients [3%] had recurrence of parasites on day 28, suggesting 
relapse. No pvmdr1 Y976F polymorphism was detected. The treatment regimen was 
well tolerated.  
20] R. Arun et al,
55
 Int J Pharm Biomed Res 2011, Simultaneous HPLC-UV method 
for the estimation of artemether and lumefantrine in tablet dosage form. the 
development and validation of a simultaneous HPLC UV method for the estimation 
of artemether and lumefantrine in fixed-dose combination tablets. The method 
showed to be linear [r2 > 0.999], precise [RSD < 0.43%], accurate [recovery of 
99.81% for artemether and 99.54% for lumefantrine], specific and robust. Three 
batches of artemether and lumefantrine tablets were assayed by the validated method. 
The artemether contents in the tablets varied from 99.30 to 99.33%, while 
lumefantrine contents were 99.65 to 99.66%.A simple isocratic RP-HPLC method 
has been developed for the simultaneous determination of artemether and 
lumefantrine using a UV detector. The method was validated for accuracy, precision, 
specificity and linearity. The method has a relatively short run time [6 min] that 
allows quantifying a large number of samples in routine and quality control analysis 
of fixed dose combination tablets. 
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3.  AIM AND OBJECTIVE 
OBJECTIVE 
                      Before carrying out a study, it’s needful to clearly defined, such that 
the study presents itself as a valuable contribution to the field of study as well as a 
thoughtful investment of researchers time. Therefore, the rationale for the study 
being planned deserves a mention. 
Rational of selection of drugs: 
Artemether
22,25
 
 It is an Antimalarial agent used to treat acute uncomplicated malaria. 
 It is administered in combination with lumefantrine for improved efficacy. 
 The drug work against the erythrocytic stages of P.falciparum by unhibiting 
nucleic acid and protein synthesis. 
 Rapid onset of action and rapid symptomatic relief  
 Half life of the Artemether is variable 3-10 hours and its active metabolite- 
dihydroartemisinin (DHA) half life- <60 min. peak plasma concentration - 2 
hours. 
Lumefantrine:
25
 
 It is administered in combination with Artemether for improved efficacy. 
 It is a blood schizonticide active against erythrocytic stages of Plasmodium 
falciparum. 
 It has a much longer half life and clears residual parasites. 
 Half life of lumefantrine ~ 4.5 days peak plasma concentration 6 to 8 hr. 
Rational of combination drug therapy
23,24
 
 Artemisinins are almost 100% effective, but recrudescence rates are high. So 
usage only in combination with longer acting drug. 
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 It causes faster parasite clearance than quinine. 
 It is safer and better tolerated than quinine. 
 Its dosing schedule is simpler. 
 Recent evidence indicates higher efficacy and lower mortality. 
 Available in fixed dose combination. 
 Lumefantrine has been used only in combination with artemether. 
 Artemether quickly reduces parasite biomass and resolves symptoms. 
 Lumeantrine prevent recrudescence.  
 This combination is used in treatment of uncomplicated chloroquine/ 
multidrug-resistant falciparum malaria. 
Rational of selection of dosage form: 
For oral, a tablet has performed as the most preferred dosage form for administration 
of drugs because of the dosage form’s ease of administration simple to manufacture 
and good stability.  
Aim and objective of the study: 
The aim of the work is to develop a stable, pharmaceutically equivalent, fixed dose 
combination of Artemether and Lumefantrine fixed dosage form.  
The objective of present study is: 
 To formulate the fixed dose combination of tablet of antimalarial activity in 
multi drug resistance falciparum malaria. 
 To develop a physic-chemically stable combination fixed dosage form. 
 To develop the process and analysis of the formulation. 
 To develop a fixed dose combination therapy dosage form that has 
comparable in vitro dissolution profile as compared to marketed product. 
 To evaluate all the parameters of formulation in detail including stability. 
 The pharmaceutically equivalent of the developed formulation is studied by 
using f1 & f2 similarity factor. 
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4.  PLAN OF WORK 
The scheme of the entire work is listed as follows: 
1. Preformulation studies 19  
 
        Preformulation involves the characterization of a drug's physical, 
chemical, and mechanical properties in order to choose what other 
ingredients should be used in the preparation. 
 Physical observation  
 Bulk density  
 Tapped density 
 Hausner’s Ratio 
 Car’s Index 
 Particle size distribution  
 Solubility  
 Compatibility studies of drug with various excipients 
2. Preparation of tablet blend. 
3.  Evaluation of Blend 
 Angle of repose 
 Bulk density and tapped density 
 Compressibility index 
 Hausner’s Ratio 
 Drug content uniformity 
4. Preparation of tablets containing excipients. 
5. Evaluation of tablets 
 Tablet appearance 
 Weight Variation 
 Hardness 
 Friability 
 Thickness 
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 Disintegration test 
 Content Uniformity 
 In vitro dissolution testing 
 Multimedia dissolution studies 
6. Comparison of the optimized formulation with the marketed 
product. 
7. Stability studies of optimized formulation. 
NUTSHELL THE PLAN OF WORK WAS AS SHOWN BELOW: 
 
LITERATURE SURVEY 
DRUG SELECTION 
EXCIPIENT SELECTION 
PREFORMULATION EVALUATION OF TRIAL 
BATCHES 
FORMULATION TRIALS 
OPTIMISATION 
SCALE-UP BATCH 
STABILITY 
STUDIES 
Packaging 
73 
 
5. DRUG & EXCIPIENT PROFILE 
1. ARTEMETHER
22,25,59,60
 
Name Artemether 
Type small molecule 
Description White Crystalline Powder 
Structure 
 
 
 
Synonyms Dihydroartemisinin methyl ether 
IUPAC Name 
10-methoxy-1,5,9-trimethyl-11,14,15,16-
tetraoxatetracyclo[10.3.1.0^{4,13}.0^{8,13}]hexadecane 
Categories  Antimalarials 
 Antiprotozoal Agents 
 Antimalarial Agents 
Weight 
Average: 298.3746 
Monoisotopic: 298.178023942 
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Chemical Formula C16H26O5 
Brand mixtures Brand Name Ingredients 
 Coartem   Artemether +   lumefantrine 
 Riamet      Artemether  +   lumefantrine 
Solubility Insoluble in water. Soluble in oil. 
Indication 
Artemether and lumefantrine combination therapy is indicated for the 
treatment of acute uncomplicated malaria caused by Plasmodium 
falciparum, including malaria acquired in chloroquine-resistant areas. 
May also be used to treat uncomplicated malaria when the Plasmodium 
species has not been identified. Indicated for use in adults and children 
greater than 5 kg. 
Pharmacodynamics 
In the body, artemether is metabolized into the active metabolite 
metabolite dihydroartemisinin. The drug works against the erythrocytic 
stages of P. falciparum by inhibiting nucleic acid and protein 
synthesis. Artemether is administered in combination with 
lumefantrine for improved efficacy. Artemether has a rapid onset of 
action and is rapidly cleared from the body. It is thought that 
artemether provides rapid symptomatic relief by reducing the number 
of malarial parasites. Lumefantrine has a much longer half life and is 
believed to clear residual parasites. 
Mechanism of 
action 
Involves an interaction with ferriprotoporphyrin IX (“heme”), or 
ferrous ions, in the acidic parasite food vacuole, which results in the 
generation of cytotoxic radical species. The generally accepted 
mechanism of action of peroxide antimalarials involves interaction of 
the peroxide-containing drug with heme, a hemoglobin degradation 
byproduct, derived from proteolysis of hemoglobin. This interaction is 
believed to result in the formation of a range of potentially toxic 
oxygen and carbon-centered radicals. 
Absorption Food increases absorption. 
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Protein binding Artemether, 95.4%; Dihydroartemisinin, 47-76% 
Metabolism Rapidly metablized to its active metabolite, dihydroartemisinin. 
Toxicity 
Common side effects of combination artemether/lumefantrine therapy 
in adults include headache, anorexia, dizziness, and asthenia. Common 
side effects in children include pyrexia, cough, vomiting, anorexia, and 
headache. Possible serious adverse effects include QT prolongation, 
bullous eruption, urticaria, splenomegaly (9%), hepatomegaly (adults, 
9%; children, 6%), hypersensitivty reaction, and angioedema. 
Affected 
organisms 
 Plasmodium 
Manufacturers  Novartis pharmaceuticals corp 
State Solid 
Experimental 
Properties 
Properties Value 
 Melting Point 86-90 
 logP 3.53 
Predicted 
Properties 
Properties Value 
 water solubility 4.57e-01 g/l 
 logP 3.02 
 logP 3.48 
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 logS -2.8 
 pKa (strongest basic) -3.9 
 physiological charge 0 
 hydrogen acceptor count 5 
 hydrogen donor count 0 
 polar surface area 46.15 
 rotatable bond count 1 
 refractivity 74.66 
 polarizability 32.12 
Drug Interaction 
Concurrent administration of artemisinin compounds with terfenadine 
Astemizole. patient should avoid the following: grapefruit juice; 
antiarrhythmics, such as amiodarone, disopyramide, flecainide, 
procainamide and quinidine; antibacterials, such as macrolides and 
quinolones; all antidepressants; antifungals such as imidazoles and 
triazoles; terfenadine; other antimalarials; all antipsychotic drugs; 
and beta blockers, such as metoprolol and sotalol. However, there 
is no evidence that co-administration with these drugs would be 
harmful 
 
Food Interaction  Grapefruit juice may increase the toxicity of artemether and 
lumefantrine by inhibiting their metabolism. 
 Take with food as food increases the absorption of artemether 
and lumefantrine. 
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2. LUMEFANTRINE
59,60
 
Name Lumefantrine 
Type Small molecule 
Description Yellow Crystalline Powder 
Structure 
 
 
Synonyms Benflumetol 
IUPAC Name 
2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-[(4-
chlorophenyl)methylidene]-9H-fluoren-4-yl]ethan-1-ol 
Categories  Antimalarials 
 Antimalarial Agents 
Weight 
Average: 528.94 
Monoisotopic: 527.154947772 
Chemical Formula C30H32Cl3NO 
Brand mixtures 
 
Brand Name Ingredients 
 Coartem artemether +   lumefantrine 
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Solubility Insoluble in water. Soluble in oil. 
Indication 
Lumefantrine and artemether combination therapy is 
indicated for the treatment of acute uncomplicated malaria 
caused by Plasmodium falciparum, including malaria 
acquired in chloroquine-resistant areas. May also be used to 
treat uncomplicated malaria when the Plasmodium species 
has not been identified. Indicated for use in adults and 
children greater than 5 kg. 
Pharmacodynamics 
Lumefantrine is a blood schizonticide active against 
erythrocytic stages of Plasmodium falciparum. It is thought 
that administration of lumefantrine with artemether results in 
cooperate antimalarial clearing effects. Artemether has a 
rapid onset of action and is rapidly cleared from the body. It 
is thus thought to provide rapid symptomatic relief by 
reducing the number of malarial parasites. Lumefantrine has 
a much longer half life and is believed to clear residual 
parasites. 
Mechanism of action 
The exact mechanism by which lumefantrine exerts its 
antimalarial effect is unknown. However, available data 
suggest that lumefantrine inhibits the formation of β-hematin 
by forming a complex with hemin and inhibits nucleic acid 
and protein synthesis. 
Absorption Food increases absorption. 
Protein binding 99.7% bound 
Metabolism 
Extensively metabolized in the liver primarily by 
cytochrome P450 3A4. The major metabolite found in 
plasma is desbutyl-lumefantrine. 
Toxicity 
Common side effects of combination 
artemether/lumefantrine therapy in adults include headache, 
anorexia, dizziness, and asthenia. Common side effects in 
children include pyrexia, cough, vomiting, anorexia, and 
headache. Possible serious adverse effects include QT 
prolongation, bullous eruption, urticaria, splenomegaly (9%), 
hepatomegaly (adults, 9%; children, 6%), hypersensitivty 
reaction, and angioedema. 
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Affected organisms Plasmodium 
Manufacturers Novartis pharmaceuticals corp. 
State solid 
Predicted Properties Properties Value 
 water solubility 3.09e-05 g/l 
 logP 8.34 
 logP 9.19 
 logS -7.2 
 pKa (strongest acidic) 14.1 
 pKa (strongest basic) 9.78 
 physiological charge 1 
 hydrogen acceptor count 2 
 hydrogen donor count 1 
 polar surface area 23.47 
 rotatable bond count 10 
 refractivity 160.81 
80 
 
 polarizability 60.69 
Drug Interaction It should not be given with drugs metabolized by CYP2D6 
(metoprolol, neuroleptics, tricyclic antidepressants, etc) or 
drugs which prolong QTc interval. 
Food Interaction  Grapefruit juice may increase the toxicity of artemether 
and lumefantrine by inhibiting their metabolism. 
 Take with food as food increases the absorption of 
lumefantrine and artemether. 
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EXCIPIENTS PROFILE
8,11
 
Micro Crystalline Cellulose
 
Non Proprietary Names 
 BP  : Microcrystalline Cellulose 
 JP  : Microcrystalline Cellulose 
 PhEur : Cellulose, Microcrystalline 
 USP-NF : Microcrystalline Cellulose 
 Synonyms : Avicel    PH;    Celex;    Cellulose    gel;  hellulosum  
microcristallinum;   Celphere;   Ceolus   KG;   
crystalline cellulose; E460; Emcocel; ethispheres .  
Structural Formula:  
 
Description: Microcrystalline cellulose is purified partially depolymerised 
cellulose that occurs as a white, odourless, tasteless, crystalline powder composed 
of porous particles. It is commercially available in different particle sizes and 
moisture grades that have different   properties and applications.  
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 Chemical Name  : Cellulose 
 Empirical Formula  : (C6H10O5) n  where n = 220 
 Molecular Weight   :  36000 
 
Functional Category:   
Adsorbent, Suspending   agent, tablet   and   capsule, diluents, tablet disintegrant. 
Stability and Storage Conditions: 
Microcrystalline cellulose is a stable through hygroscopic material. The bulk 
material should be stored in a well-closed container in a cool, dry place. 
Incompatibilities:  
Microcrystalline cellulose is a incompatible with strong oxidizing agents. 
Applications  
Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a 
binder/diluents in oral tablet and capsule formulations where it is used in both wet 
granulation and direct-compression processes.  In addition to its use as a 
binder/diluents, microcrystalline cellulose also has some lubricant and disintegrant 
properties that make it useful in tableting.  
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MAGNESIUM STEARATE
 
Synonyms Stearic acid magnesium salt, magnesium salt, magnesium 
octadecanoate 
Description 
If is a fine, white, precipitated of milled, impalpable 
powder of low bulk density, having a faint odor of stearic 
acid & a characteristic taste. 
Structural 
Formula 
[CH3(CH2)16COO]2Mg 
Empirical 
Formula & 
Molecular Weight 
C36H70MgO4  ; 591.34 
Solubility 
It is insoluble in water, ethanol & ether, slightly soluble in 
warm benzene & warm ethanol 
Functional 
categories 
Table & capsule lubricant 
Melting point 117- 150°C 
Density (bulk) 
Density (tapped) 
0.159gm/cm
3
 
0.286gm/cm
3
 
Stability and 
storage conditions 
Should be stored in well-closed container in a cool, dry 
place. It is stable compound. 
Incompatibilities 
Incompatible with strong oxidizing agents, strong acids, 
alkalis & iron salts. It cannot be used in products containing 
aspirin, some vitamins, & most alkaloidal salts. 
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Safety 
It is nontoxic. However, oral consumption of large quantity 
may result in some laxative effect or mucosal irritation. 
Applications 
Used in cosmetics, food & pharmaceutical formulations and 
as a lubricant in capsule & table at concentration between 
0.25-5.0%. 
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COLLOIDAL SILICONE DIOXIDE (AEROSIL)
 
Nonproprietary Names  
 BP : Colloidal anhydrous silica 
 PhEur : Silica colloidalis anhydrica 
 USPNF : Colloidal silicon dioxide 
 Synonyms : colloidal silica, fumed silica, light anhydrous 
silicic   acid,   silicic   anhydride  and  silicon 
dioxide fumed 
 Chemical Name : Silica 
 Molecular Weight : 60.08 
  PH                                 :     3.5-5.5 
 Loss on drying               :     ≤ 2.5% 
          Density (bulk)                 :  0.029 – 0.042 gm / cm3 
 Functional Category  :  SiO2   is an Adsorbent,    anticaking    agent,    
emulsion        stabilizer,  glident,  suspending 
agent, tablet disintegrant, thermal stabilizer, 
and viscosity-increasing agent.  
Applications in Pharmaceutical Formulation or Technology:  
Colloidal silicon dioxide is widely used in pharmaceuticals, cosmetics, and food 
products. Its small particle size and large specific surface area gives desirable flow 
characteristics that are exploited to improve the flow properties of dry powders in a 
number of processes such as tabletting.  
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Description: 
 Colloidal silicon dioxide is submicroscopic fumed silica with a particle size 
of about  15 nm.  It is a  light,  loose,  bluish-white-colored,  odorless,  tasteless,  and non-
gritty amorphous powder.  
Stability and Storage Conditions:  
Colloidal silicon dioxide is hygroscopic but adsorbs large quantities of water 
without liquefying. When used in aqueous systems at a pH 0-7.5, colloidal silicon 
dioxide is effective in increasing the viscosity of a system. However, at a pH greater 
than 7.5 the viscosity-increasing properties of colloidal silicon dioxide are reduced; 
and at a pH greater than 10.7 this ability is lost entirely since the silicon dioxide 
dissolves to form silicates. Colloidal silicon dioxide powder should be stored in 
a well-closed container. Some grades of colloidal silicon dioxide have 
hydrophobic surface treatments that greatly minimize their hygroscopicity.  
Incompatibilities:   
Incompatible with diethylstilbestrol preparation 
Safety:  
It is widely used in oral and topical pharmaceutical formulation and is generally 
regarded as a nontoxic and nonirritant material. Intraperitonial and subcutaneous 
injection may produce local tissue radiations and or granulomas.  
Applications:  
It is widely used in pharmaceuticals, cosmetics, and food products. It is mainly used as 
a glidant for tableting. 
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ISO PROPYL ALCOHOL
29
 
Nonproprietary names   :   BP  - isopropyl alcohol 
     JP – isopropanol 
     Ph EUR – alcohol isopropylicus 
 Empirical formula  :          C3H8O 
Chemical name      :           Propan-2-ol 
Structural formula        :  
Molecular weight    :         60.1 g/mol 
Description             :         It is a clear color less, mobile, volatile,  
flammable,liquid with a characteristic spirituous 
odour resembling that of amixture of ethanol and 
acetone, it has a slight bitter taste. 
 Functional categories  :         Disinfectant and solvent 
Solubility                  :       Miscible with benzene, chloroform,  
  Ethanol (95%), ether   and water  
 
 Melting point             :     88.5°C 
 Flash point                :    11.7°C (closed cup) and 10° C (open cup) 
 Moisture content      :    0.1-13 %w/w; commercial grades-13 %w/w. 
Stability and storage: stored in well-closed 
container in a cool and dry place 
 
Applications               :        Used in lotions, used as a solvent both for tablet  
           film coating, Granulation and topical disinfectant 
 
Incompatibilities            :  Incompatible with oxidizing agents such as 
hydrogen-per-oxide and nitric acid, which cause 
decomposition.  IPA may be salted out from 
aqueous mixtures by the addition of sodium 
chloride and other salts or by the addition of 
sodium hydroxide. 
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HYDROXYPROPYL CELLULOSE 
Chemical structure: 
 
 
 
Nonproprietary Name 
BP  :  Hydroxypropyl cellulose 
Ph .Eur :  Hydroxypropyl cellulosum 
USP  :  Hydroxypropyl cellulose 
Synonyms :  Cellulose Hydroxypropyl Ether; E463; Hyprolose; Klucel; 
Methocel; Nisso HPC ; Oxypropylate Cellulose. 
Description    :  Hydroxypropyl cellulose is a white to slightly yellow-colored        
odorless and tasteless powder. It may contain not more than 
0.6% of silica some other suitable anticaking agent. 
Hydroxypropyl cellulose is commercially available in number 
of different grades which have different solution viscosity. 
 
89 
 
Solubility       :  Hydroxypropyl cellulose is freely in water below 38 c forming 
a smooth, clear, colloidal solution. It is soluble in cold or hot 
polar organic solvent such as; dimethyl formamide; dimethyl 
sulfoxide ethanol. 
Application :  Hydroxypropyl cellulose is widely used oral and tropical 
pharmaceutical formulation. In oral product, hydroxypropyl 
cellulose is primarily used in tableting as binder, film-coating 
and extended release matrix 
Use Concentration (%) 
Extended release matrix 15-35 
Tablet binder 2-6 
Tablet film-coating 5 
Incompatibilities:  Hydroxypropyl cellulose is incompatibilities with substituted 
phenol derivatives such as methylparaben propylparaben 
Stability             :  Hydroxypropyl Cellulose powder is stable material although it 
is hygroscopic after drying. 
Storage Condition:  Hydroxy propyl Cellulose powder should be stored in well 
closed container in cool, dry, place. 
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CROSCARMELLOSE SODIUM 
Nonproprietary Names: 
BP :  Croscarmellose Sodium 
JP :  Croscarmellose Sodium 
PhEur :  Croscarmellose Sodium 
USP-NF :  Croscarmellose Sodium 
Synonyms : Ac-Di-Sol; carmellosum natricum conexum; crosslinked 
carboxymethylcellulose sodium; Explocel; modified cellulose 
gum; Nymcel ZSX; Pharmacel XL; Primellose; Solutab; 
Vivasol. 
Chemical Name and CAS Registry Number: 
Cellulose, carboxymethyl ether, sodium salt, crosslinked [74811- 65-7] 
Empirical Formula and Molecular Weight: 
Croscarmellose sodium is a crosslinked polymer of carboxymethylcellulose sodium. 
Structural Formula: 
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Functional Category: 
Tablet and capsule disintegrant. 
Applications in Pharmaceutical Formulation or Technology: 
Croscarmellose sodium is used in oral pharmaceutical formulations as a disintegrant 
for capsules,(1,2) tablets,(3–13) and granules. In tablet formulations, croscarmellose 
sodium may be used in both direct-compression and wet-granulation processes. 
When used in wet granulations, the croscarmellose sodium should be added in both 
the wet and dry stages of the process (intra- and extragranularly) so that the wicking 
and swelling ability of the disintegrant is best utilized.(11,12) Croscarmellose 
sodium at concentrations up to 5% w/w may be used as a tablet disintegrant, 
although normally 2% w/w is used in tablets prepared by direct compression and 3% 
w/w in tablets prepared by a wet-granulation process.  
Use Concentration:  (in %) 
Disintegrant in capsules 10–25 
Disintegrant in tablets 0.5–5.0 
 Description: 
Croscarmellose sodium occurs as an odorless, white or grayish white powder. 
 Typical Properties: 
Acidity/alkalinity pH = 5.0–7.0 in aqueous dispersions. 
Bonding index 0.0456 
Brittle fracture index 0.1000 
Density (bulk) 0.529 g/cm3 for Ac-Di-Sol 
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Stability and Storage Conditions: 
Croscarmellose sodium is a stable though hygroscopic material. A model tablet 
formulation prepared by direct compression, with croscarmellose sodium as a 
disintegrant, showed no significant difference in drug dissolution after storage at 
308C for 14 months.(9) Croscarmellose sodium should be stored in a well-closed 
container in a cool, dry place. 
 Incompatibilities: 
The efficacy of disintegrants, such as croscarmellose sodium, may be slightly 
reduced in tablet formulations prepared by either the wet-granulation or direct-
compression process that contain hygroscopic excipients such as sorbitol.  
Croscarmellose sodium is not compatible with strong acids or with soluble salts of 
iron and some other metals such as aluminum, mercury, and zinc. 
Safety: 
Croscarmellose sodium is mainly used as a disintegrant in oral pharmaceutical 
formulations and is generally regarded as an essentially nontoxic and nonirritant 
material. However, oral consumption of large amounts of croscarmellose sodium 
may have a laxative effect, although the quantities used in solid dosage formulations 
are unlikely to cause such problems. In the UK, croscarmellose sodium is accepted 
for use in dietary supplements. The WHO has not specified an acceptable daily 
intake for the related substance carboxymethylcellulose sodium, used as a food 
additive, since the levels necessary to achieve a desired effect were not considered 
sufficient to be a hazard to health. 
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POLYSORBATE 80 
Synonym :  TWEEN 80; Polyoxyethylene 20 sorbitan monooleate; 
Polyethylene oxide sorbitan mono-oleate; Polyoxyethylene 
sorbitan monooleate; Polyoxyethylene sorbitan oleate; 
Sorbitan mono-9-octadecenoate poly(oxy-1,2-ethanediyl) 
derivatives; Sorethytan (20) monooleate 
Chemical Name :  Sorbitan, monooleate polyoxyethylene derivative. 
Physical state and appearance: Liquid. (Oily liquid.) 
Odor :  fatty (Slight.) 
Color :  Clear Amber. Yellow. 
pH (1% soln/water):  7 [Neutral.] 
Boiling Point :  >100°C (212°F) 
Melting Point :  -20.556°C (-5°F) 
Specific Gravity :  1.06 - 1.10 (Water = 1) 
Solubility :  Easily soluble in cold water, hot water. Soluble in methanol. 
Soluble in Toluene, alcohol, cottonseed oil, corn oil, Ethyl 
Acetate. Insoluble in mineral oil.. 
Incompatibility with various substances:  
Reactive with oxidizing agents. 
Corrosivity:  
Non-corrosive in presence of glass, of stainless steel(304), of stainless steel(316). 
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Structure:
 
Food use: 
Polysorbate 80 is used as an emulsifier in foods, particularly in ice cream. Here, 
polysorbate is added to up to 0.5% (v/v) concentration and makes the ice cream 
smoother and easier to handle, as well as increasing its resistance to melting.
[4]
 
Adding this substance prevents milk proteins from completely coating the fat 
droplets. This allows them to join together in chains and nets, which hold air in the 
mixture, and provide a firmer texture that holds its shape as the ice cream melts. 
Medical use: 
Polysorbate 80 is an excipient that is used to stabilize aqueous formulations of 
medications for parenteral administration, and used as an emulsifier in the 
manufacture of the popular anti-arrhythmic amiodarone.
[5]
 It is also used as an 
excipient in some European and Canadian influenza vaccines.
[6]
 It is also used in the 
culture of Mycobacterium tuberculosis in Middlebrook 7H9 broth. 
 Laboratory use: 
Some mycobacteria contain a type of lipase (enzyme that breaks up lipid molecules). 
When added to a mixture of Tween 80 and phenol red, they cause the solution to 
change colour, so this is used as a test to identify the phenotype of a strain or isolate. 
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Molecular formula C64H124O26 
Molar mass  1310 g/mol 
Appearance Amber colored viscous liquid 
Density 1.06–1.09 g/mL, oily liquid 
Boiling point  > 100°C 
Solubility in water Very soluble 
Solubility in other 
solvents 
soluble in ethanol, cottonseed oil, corn 
oil, ethyl acetate, methanol, toluene 
Viscosity 300–500 centistokes (@25°C) 
Main hazards Irritant 
Flash point  113 °C 
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6. MATERIALS AND EQUIPMENTS 
 
API, excipients and equipments used for the development of formulation:  
 
 
 
S.No. Materials Suppliers 
1 
 
Artemether                              
 Mangalam drugs Pvt 
2 Lumefantrine                           Mangalam drugs Pvt 
3 Hydroxyl propyl cellulose  
Welming pharmaceuticals, 
India 
4 Polysorbate 80 Welming chemicals,india 
5 Iso propyl alcohol                                          
Loba chemie.,pvt ltd,. 
Mumbai 
6 Microcrystalline cellulose       Welming chemicals, India 
7 Croscarmelose sodium            S.D.Fine-Chemi.,Pvt Ltd., 
Mumbai 
8 Aerosil                                     Amaratal & Co., Chennai 
9 Magnesium stearate                 Loba chemie., Pvt. Ltd., 
Mumbai 
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 Equipments used for formulation and analysis purpose 
 
S.No. Equipments Manufacturer 
1 
Tablet compression machine - 12 station (Single 
Rotary) 
CIP Machinery 
2 Die & Punch CIP Machinery 
3 Planetary Mixer                                    Kenwood 
4 Hot air oven Lab India 
5 Dissolution apparatus(usp) Electro Lab 
6 Electromagnetic sieve shaker (ESM- 8) Electrolab 
7 Tablet Hardness tester (8M) 
Dr.Schleuniger,pharmaton,
USA 
8 PH meter Lab India 
9 
Reverse phase High Pressure Liquid 
chromatograph (HPLC) 
Shimadzu 
10 UV visible spectrophotometer Perkin Elmer 
11 Electronic Weighing Balance Essac Teraoka Ltd (Japan) 
12 Digital high precision balance (single pan) 
Mettler – Toledo 
(switzerland) 
13 Disintegration tester Electro Lab 
14 Roche Friabilator USP Electro Lab 
15 Mechanical stirrer Remi Motors, Bombay. 
16 Tabbed density tester Electro lab 
17 Bulk density apparatus Electro lab 
18 Stability chambers Thermo lab, Mumbai 
19 Sieves (A.S.T.M) Rajdhani 
20 Digital Vernier Calipers CD-6 inch CSX Mitutoyo Corp, Japan 
21 Blister Packing Machine 
Precision Gears 
Ltd.IMA,Italy 
22 Humidity Chamber HTC 3003 Thermolab 
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7. EXPERIMENTAL WORK  
PREFORMULATION STUDY
19
 
 
Preformulation studies can be defined as an investigation of physical and chemical 
properties of active pharmaceutical ingredient, alone and in combination with excipients. 
It is the first step in rational development of a formulation or dosage form. 
The objective of Preformulation studies is to generate information useful to the 
formulator in developing stable and bioequivalent dosage form. Obviously the types of 
information needed will depend on the dosage form to be developed. 
Evaluation of Drug: 
 
It is the first step in rationale development of a formulation or dosage form of a drug 
substance. Preformulation studies can be defined as an investigation of physical and 
chemical properties of active pharmaceutical ingredient, alone and in combination with 
excipients. 
Scope:  
The use of Preformulation parameters maximizes the chances in formulating an 
acceptable, safe, efficacious and stable product and at same time provides the basis for 
optimization of the drug product quality. 
The formal preformulation study is start at the point after biological screening. When a 
decision is made for the further development of the compound in clinical trials - 
embarking on a formal program. 
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Preliminary activities in this drug product development project started with a 
comprehensive review of authoritative reference books on the pharmaceutical and 
analytical parameters and attributes of the chosen drug.  
The preformulation scientist must consider the following: 
 Available Pharmacokinetic data. 
 Anticipated dose 
 Supply situation and development schedule. 
 Nature of the information the formulator should have or would like to have. 
The above considerations will offer the preformulation scientist some guidelines in 
deciding the types and the urgency of the studies that need the attention. 
Preformulation studies: 
1. Evaluation of drug 
 Description 
 Melting point 
 Solubility 
 Water content by Loss on Drying 
 Hygroscopic Nature 
2. Differential scanning calorimetry – to analyse the incompatibility of the drug with the 
polymer 
3. Physical evaluation of the granules 
 Bulk Density 
 Tapped density 
 Carr’s Index 
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 Haunser’s Ratio 
 Angle of Repose 
 
4. Evaluation of the formulated tablet 
 Friability 
 Hardness 
 Thickness 
 Uniformity of weight 
 Swelling and erosion study 
 Assay 
 In vitro drug release 
 Stability Study 
 Release kinetics 
 
Description: 
 
 About 1g Artemether and lumefantrine of sample is taken in a dry petridish and 
the sample is observed for compliance against the specification. 
Observation: Artemether – white crystalline powder. Lumefantrine – yellow 
crystalline powder 
 
Identification of pure drug: Identification of artemether and lumefantrine is carried out 
by Infra Red Absorption Spectrophotometry. 
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Melting Point Determination:
29 
Melting Point Determination of Artemether 
Sample Melting point (˚C) 
Reference Range (˚C) 
(IP) 
 1 2  
Artemether 86-88 86-89 86 – 90 
Table No.24 
Melting Point Determination of Lumefantrine: 
Sample Melting point (˚C)  Reference Range 
(˚C)  
(IP) 
 1 2  
Lumefantrine 128 - 130 128 - 131 128 – 132 
Table No.25 
The melting point of the sample agreed with the literature value of 86-90˚C as stated in 
the IP, further confirming the sample as Artemether and also ascertaining its purity. 
The melting range of the sample was 128–130˚C and this agreed with the literature value 
of 128–132˚C. as stated in the USP SALMOUS Standard. 
Organoleptic properties: The color, odor and taste of the drug were recorded using 
descriptive terminology.
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Organoleptic 
properties
 
 
          Artemether 
 
Lumefantrine 
 
Colour 
 
white crystals 
 
yellowish powder 
 
Odour 
 
Odourless 
 
Odourless 
 
Taste 
 
Slightly Bitter 
 
Bitter 
 
Microscopic 
examination 
 
Crystalline powder 
 
Amorphous powder 
Table No.26 
 
Solubility Studies:
22
 
The spontaneous interaction of two or more substance to form a homogeneous molecular 
dispersion is called as solubility. The solubility of Artemether and Lumefantrine was 
studied in various solvents. The solubility profiles of Artemether and Lumefantrine in 
various solvents are shown in the Table. The approximate solubility’s of substances are 
indicated by the descriptive 
terms in the accompanying table. 
 
Descriptive term 
Parts of solvent required for 
1 part of solute 
Very soluble Less than 1 
Freely soluble From 1 to 10 
Soluble From 10 to 30 
Sparingly soluble From 30 to 100 
Slightly Soluble From 100 to 1000 
Table No.27 
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Solubility Profile of Artemether: 
 
S. No Solvent Solubility 
1 Distilled water Insoluble 
2 PBS (pH 6.8) Soluble 
3 Acetonitrile Soluble 
4 0.1 N HCL Soluble 
5 Ethanol Soluble 
6 Dichloromethane Soluble 
Table No.28 
Solubility Profile of Lumefantrine: 
 
S. No Solvent Solubility 
1 Distilled water Insoluble 
2 PBS (pH 6.8) Soluble 
3 Acetonitrile Soluble 
4 0.1 N HCL Soluble 
5 Ethanol Soluble 
6 Dichloromethane Soluble 
Table No.29 
Determination of particle size:
17
 
Sieve analysis: 
The main aim of sieve analysis is to determine the different size of drug particles 
present. A series of standard sieve were stacked one above the other so that sieves with 
larger pore size (less sieve number) occupy top position followed by sieves with smaller 
pore size (greater sieve number towards the bottom). 
104 
 
Procedure: 
A series of sieves were arranged in the order of their decreasing pore diameter 
(increasing sieve number) i.e. sieve number 20, 30, 40, 60, 100, and 200. 100 grams of 
drug was weighed accurately and transferred to sieve number 20 which were kept on 
top. The sieves were shaken for about 5-10 minutes on mechanical sieve shaker having 
bottom tap motion. Then the drug retained on each sieves was taken, weighed separately 
and amount retained was expressed in terms of percentage. 
 
Observation of particle size of Artemether: 
Sieve No. 
Weight 
retained 
(gm) 
% Retained 
Cumulative % 
Retained 
% passed 
20 0.3282 1.9912 1.9912 98.0088 
40 6.180 37.5201 39.5113 60.4887 
60 8.3150 50.4495 89.9608 10.0392 
100 0.3409 2.0683 92.0291 7.9709 
Base plate 0.1580 0.9586 -- -- 
Table No.30 
Observation of particle size of Lumefantrine: 
Sieve No. Weight retained (gm) % Retained 
Cumulative 
% Retained 
% passed 
20 0.381 2.1404 2.1404 97.8596 
40 1.432 8.0449 10.1853 89.8147 
60 5.890 33.089 43.2743 56.7257 
100 8.931 50.174 93.4483 6.5517 
Base plate 1.233 6.9269 -- -- 
Table No.31 
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Determination of Bulk density:
 12
 
Bulk density is defined as a mass of a powder divided by the bulk volume. A sample 
powder of Active pharmaceutical ingredient was introduced in 100 ml graduated 
cylinder. The volume of the material was noted on graduated cylinder. The bulk density 
was calculated by the formula given below. 
 Bulk density (ρ0) = M/Vo 
Where, M = mass of the powder  
 Vo = volume of the powder  
Determination of Tapped Density:
 12 
The powder sample under test was screened through sieve no. 18 and the weight of 
sample equivalent to 10 g was filled in 100 ml graduated cylinder. The mechanical 
tapping of the cylinder was carried out at a rate of 300 drops per minute for 500 times 
from 3” height and the tapped volume Vf was noted.  
The tapped density was calculated in gm/ cm
3
 by the formula, 
Tapped density (ρt) = M/Vf 
Where, M = weight of sample powder taken 
Vf = tapped volume 
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Determination of Flow properties:
19
 
Hausner’s Ratio: 
It indicates the flow properties of the powder and is measured by the ratio of tapped 
density to bulk density. 
 Hausner’s Ratio = Tapped density / Bulk density 
Compressibility index (Carr’s indices): 
Compressibility index is an important measure that can be obtained from the bulk and 
tapped densities. In theory, the less compressible a material the more flow able it is. A 
material having values of less than 20 to 30% is defined as the free flowing material.  
 Ci =  (V0 – Vf ) × 100         
           V0  
Compressibility index specifications 
% Comp. Index Properties Hausner’s ratio 
≤10 Free flowing 1.00 – 1.11 
11 -15 Good 1.12 – 1.18 
16 – 20 Fair 1.19 – 1.25 
21 – 25 Passable 1.26 – 1.34 
26 – 31  Poor 1.35 – 1.45 
32 – 37 Very poor 1.46 – 1.59 
≥38 Extremely poor >1.60 
Table No.32 
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Angle of repose: 
It is the maximum angle that can be obtained between the freestanding surface of the 
granules heap and the horizontal plane. 
tan θ = h/r 
If the angle of repose is less than 30º then the granules is considered to be free flowing. 
Flow properties and corresponding Angle of Repose: 
Angle of Repose (in degrees) Flow property 
25 – 30 Excellent 
31 – 35 Good 
36 – 40 Fair – Aid not required 
41 – 45 Passable – May hang up 
46 – 55 Poor – Mast agitate, vibrate 
56 – 65 Very poor 
>66 Very. Very poor 
Table No.33 
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Observation of Density and Flow parameter: 
Raw Material 
Density (g / ml) Flow properties 
Bulk Tapped Carr’s index 
Hausner’s 
ratio 
Angle of 
Repose 
Artemether 0.3667 0.6875 46.661 1.8748 34.18 
Lumefantrine 0.612 0.760 19.41 1.24 36.17 
Table No.34 
Conclusion: The above observation indicates that Artemether and Lumefantrine drug has 
very poor flow properties. 
Calibration Curve:  
Artemether:
25
 
50mg of pure Artemether was weighed and made up to 100ml with methanol. 5ml of the 
Artemether stock solution above was added to corresponding volumes of the prepared 
Artemether solution and made up to the 25ml mark in a 25ml volumetric flask with the 
mobile phase giving concentrations of 0.044, 0.048, 0.052, 0.056 and 0.060%w/v. The 
solutions were injected using indometacin at a concentration of 0.00008%w/v as an 
external standard. 
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Concentration (%W/V) Average peak area ratio 
0.002240 0.0616 
0.004480 0.1268 
0.008960 0.2246 
0.013440 0.3188 
0.017920 0.4094 
0.022400 0.5072 
0.026880 0.6087 
 
 
Fig.No.7 
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Parameters of Calibration Curve Value 
Range 0.002240%w/v - 0.026880%w/v 
Slope 21.747  
Intercept 0.0200 ± 0.0050 
R
2
 0.9991 
 
Calibration Curve:  
Lumefantrine
29
 
Approximately 20mg of Lumefantrine was accurately weighed and dissolved with 0.1M 
methanolic HCl to the 200ml mark in a volumetric flask. From this stock solution, 
solutions with concentrations of 0.0008, 0.0012, 0.0016, 0.0020, 0.0024 and 
0.0028%w/v were prepared by serial dilution. The absorbances of these solutions at 
335nm were obtained with 0.1M methanolic HCl as blank and used in the plotting of a 
calibration curve. 
Conc. (% w / v ) Average Absorbance 
0.0008 0.265 
0.0012 0.392 
0.0017 0.536 
0.0021 0.665 
0.0025 0.790 
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Fig.No.8 
 
Calibration Curve Parameters Value 
Range 0.0008%w/v – 0.0028%w/v 
Slope 307.16 ± 2.90 
Intercept 0.0073 ± 0.0054 
R
2
 0.9997 
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Chromatogram of Artemether for determining λmax:
32,33
 
λmax of Artemether – 254 nm 
 
Fig No.9 
Chromatogram of Lumefantrine for determining λmax: 
λmax of  Lumefantrine– 335 nm 
 
Fig. No.10 
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FTIR Studies 
IR spectra for drug, and powdered tablets were recorded in a Fourier transform infrared 
spectrophotometer (FTIR 1615, Perkin Elmer, USA) with KBr pellets. One of the 
requirements for the selection of suitable excipients or carrier for pharmaceutical 
formulation is its compatibility. Therefore in the present work, a study was carried out 
by using infrared spectrophotometer to find out if there is any possible interaction 
between the drug and excipients. Weighed amount of drug (3mg) was mixed with 100 
mg of potassium bromide (dried at 40-50°C). The mixture was taken and compressed 
under 10-ton pressure in a hydraulic press to form a transparent pellet. The pellet was 
scanned from 4000-400 cm
-1
 in IR spectrophotometer.  
DRUG-EXCIPIENT COMPATIBILITY STUDY: 
 
In this study the active pharmaceutical ingredient and excipients (different type) are mixed 
and stored at different conditions for variable time periods. 
The physical properties (colour change) were monitored regularly. The change in color 
in any mixture was the basis for disregarding from study. 
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Different ratios of Drug and excipient taken for Compatibility Study 
Name of  the 
Excipients 
Ratio 
Initial 
( 0 days) 
Final observation 
Conclusion 40 ° C / 75 % RH 
2nd week 5th week 
Artemether+ 
Lumefantrine 
1:1 
Yellow 
Crystalline 
powder 
Yellow 
crystalline 
powder 
Yellow 
crystalline 
powder 
Compatible 
AL + MCC 1:1 
Yellow 
crystalline 
powder 
Yellow 
crystalline 
powder 
Yellow 
crystalline 
powder 
Compatible 
AL + Mg. 
Stearate 
1:1 
Yellow 
crystalline 
powder 
Yellow 
crystalline 
powder 
Yellow 
crystalline 
powder 
Compatible 
AL + Aerosil 1:1 
Yellow 
crystalline 
powder 
Yellow 
crystalline 
powder 
Yellow 
crystalline 
powder 
Compatible 
AL + HPC 1:1 
Yellow 
amorphous 
powder 
Yellow 
amorphous 
powder 
Yellow 
amorphous 
powder 
Compatible 
AL + Isopropyl 
alcohol 
1:1 
Yellow 
amorphous 
powder 
Yellow 
amorphous 
powder 
Yellow 
amorphous 
powder 
Compatible 
AL + CCS 1:1 
Yellow 
crystalline 
powder 
Yellow 
crystalline 
powder 
Yellow 
anhydrous 
powder 
Compatible 
AL + 
Polysorbate 80 
1:1 
Yellow 
amorphous 
powder 
Yellow 
amorphous 
powder 
Yellow 
anhydrous 
powder 
Compatible 
Table No.35 
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INNOVATOR CHARACTERIZATION 
 
 
Brand Name : Coartem 
 
Strengths available :  20 mg + 120 mg  
 
 Innovator product information 
 
Product information   : Coartem – Tablets (Artemether  20 mg+ 
Lumefantrine 120mg) 
 
Route of administration    :  Oral 
 
Dosage form  : Tablet 
 
Colour  : Yellow 
 
Shape : Round 
 
Average weight of 10 tablets : 2.40 g (240 mg / tab) 
 
Average thickness of 10  tablets : 3.12 mm 
 
Average Diameter of 10 tablets  : 9.5 mm 
 
Description : Yellow Colored, un-coated round tablet. 
 
Package description :  24 tablets in 1 blister pack  
 
Storage conditions  : Store at or below 25°C (77°F) 
 
Manufacturer :  NOVARTIS 
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FORMULATION DEVELOPMENT 
PROCESS DEVELOPMENT: 
The process for formulation of Artemether  and lumefantrine was developed in a 
systematic way. Trials were taken by wet granulation tabletting process with hydrophilic 
polymers. 
TECHNIQUE SELECTION - WET GRANULATION 
Manufacturing procedure:  
 
 Milling and mixing of drug and excipients 
The Artemether and lumefantrine  active drugs was weighed accurately as 
mentioned in the formula and was mixed with MCC, part of aerosil  and sifted 
through sieve no #100. The blend containing drug and other raw material were 
mixed in an octagonal blender for 15 minutes. 
 
 Preparation of binder solution 
Weigh HPC RTLF add to required quantity of polysorbate 80 and IPA and stirr 
for 45mins. 
 
 Wet massing by the addition of binder solution 
The above binder solution added to dry mixture to form wet mass. 
 
 Screening of wet mass 
The wet mass passed through 12# mesh. 
 
 Drying of the wet granules 
The screened wet granules were kept in tray drier at 60ºC. 
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 Screening of dry granules 
The dried granules passed through 20# mesh. 
 
 Blending of dried granules with diluent and disintegrants 
Weigh accurately aerosil, Croscarmellose sodium was passed through 40# mesh 
and add to dried granules and mix for 3mins. 
 
 Addition of Lubricant to produce free flow powder 
Previously sifted (sieve no #40) magnesium stearate was added to the granular 
blend and lubricated for 2mins. Then this final blend was mixed in an octagonal 
blender for 10 minutes. 
 
 Compression 
The final lubricated blend was compressed using 19.2 x 11.6mm, oval shaped 
punch to get the target weight and adequate hardness. 
 
Photo copy of Compressed uncoated tablets 
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PROCESS FLOW CHART 
Weighing of required granules 
Pass lumefantrine through 200 # 
Adding  excipients MCC(half quanty) , aerosil (half qty)previously passed 40 # 
Preparing the binder solution 
Binder + Dry mix  
       Wet mass 
Drying of wet granules 
Screening of dried granules 
         Blending of dried granules with Artemether + MCC (remaining half qty)+ Aerosil 
(remaining half qty)+ CCS + Mg. Sterate 
 
Compression 
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Different trial formulations: 
INGREDIENTS F1 F2 F3 F4 F5 F6 
Lumefantrine 120.00 120.00 120.00 120.00 120.00 120.00 
Artemether 20.00 20.00 20.00 20.00 20.00 20.00 
Microcrystalline 
cellulose 
84.75 81.5 80.5 78.50 80.50 80.50 
Aerosil 5.00 4.75 4.00 3.50 4.00 4.00 
Hydroxyl propyl 
cellulose 
0.25 0.75 1.50 2.00 1.50 1.50 
Croscarmellose 
sodium 
2.00 4.00 5.00 7.00 - - 
Crospovidone - - - - 5.00 5.00 
Magnesium stearate 6.00 6.00 6.00 6.00 6.00 6.00 
Polysorbate 80 2.00 3.00 3.00 3.00 3.00 3.00 
Iso propyl alcohol 
Qs ( 80 
ml ) 
Qs ( 80 
ml ) 
Qs ( 80 
ml ) 
Qs (80 
ml) 
Qs (80 
ml) 
Qs (80 
ml) 
       Trial Batch F5 & F6 = Failure 
Table No.36 
Punch sets description: 
Item Standards 
Upper punch 9.1 mm Flat circular punch with break line 
Lower punch 9.1 mm Plain flat circular punch  
Dies Circular (Round)shape 
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Table No.37 
 Tablet Parameters as follows: 
Parameters Specification  
Description 
Yellow, circular, flat, beveledged uncoated tablet 
having a breakline on oneside and otherside plain. 
Theoretical mass of tablet 240.00 mg 
Average mass 240.0 mg ± 5.0%  
Uniformity of mass 
NMT 2/20 individual mass deviate from ± 7.5% of 
the average mass. 
Diameter 9.00 ± 0.10 mm  
Thickness 3.00 ± 0.30 mm 
Hardness 4 – 5 kg / cm2 
Friability   NMT 1.0 %m/m.  
Disintegration time  NMT 15 minutes in water at 37
0
 ± 2
0
C 
 
Table No.38 
Parameters for evaluation of designed formulation: 
 
1. Pre-compression parameter evaluation  
 Granules evaluation (Lubricated blend) 
 Particle size 
 Density  
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 Loss on drying 
 Flow properties 
 Compressibility 
2. Post-compression parameter evaluation: 
 Tablet evaluation 
 
 Description  
 Appearance  
 Weight variation 
 Thickness  
 Hardness  
 Uniformity of weight 
 Friability  
 In Vitro Dissolution Studies (Mathematical model of in vitro dissolution) 
 Assay  
 
3. Accelerated Stability Study: 
 Stability study as per ICH Guidelines 
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 Granules evaluation:
22
  
Particle size, density, loss on drying (moisture content), flow properties, and 
compressibility of the granules was determined similar to text characterized in 
preformulation  study. 
Particle size determination 
Sieving is the most widely used method for measuring particle size distribution because 
it is inexpensive, simple, and rapid with little variation between operators The procedure 
involves the mechanical shaking of a sample through a series of successively smaller 
sieve, and weighing of the portion of the sample retained on each sieve. The type of 
motion influence sieving: vibratory motion is the most efficient, followed successively 
by side tap motion, bottom tap motion, and rotary motion with tap and rotary motion. 
Time is the important factor in sieving. The load or thickness of powder per unit area of 
sieve influences the time of sieving; for a given set of sieves, the time required to sieve a 
given material is roughly proportional to the load placed on the sieves, the type of 
motion, time of sieving, and load should be standardized. 
Method:  
Particle size distribution was determined by using sieve shaker. Approximately weighed 
amount i.e. 10g of a sample under study was kept at the top of the sieve, arranged in 
descending order of mesh size # i.e. 590μ, 420 μ, 250 μ, 149 μ, 74 μ and the base pan. 
The assembly was tightly   closed and allowed to vibrate for 10 min at 10 HP. The 
amount of powder retained on each sieve was calculated. 
 
 
123 
 
 
Classification of powders depending on the particle size: 
 
S.NO. Type of Powder 
Should Completely 
passing 
Through (Mesh no#) 
 
NMT 60% should 
pass 
through (Mesh no#) 
 
1 Coarse Powder 20 40 
2 
Moderately Coarse Powder 
 
40 60 
3 Fine Powder 80 120 
4 Very Fine Powder 120 No limit 
 
Table No.39 
 
Angle of repose: 
 
The flow property was determined by measuring the Angle of Repose. It is the 
maximum angle that can be obtained between the freestanding surface of a powder heap 
and the horizontal plane. Values of q are rarely less than 20°, and values of up to 40° 
indicate reasonable flow potential. Above 50o, however, the powder flows only with 
difficulty if at all. 
                                                               θ = Tan-1 (h/r) 
                                        Where, 
                                                                h = height the pile. 
                                                                r = radius of the pile. 
                                                               θ = Angle of repose. 
124 
 
5 grams of the sample was taken in a funnel fixed in a holder, 6 cm above the surface at 
an appropriate height and a graph of sheet was placed below the funnel. The sample was 
passed through the funnel slowly. The height of the powder heap formed was measured. 
The circumference of the heap formed was drawn with a pencil on the graph paper. The 
radius was measured and the angle of repose was determined using the above formula. 
This was repeated 3 times for a sample. 
 
Determination of bulk density and tapped density: 
A quantity of 20 g of the powder (W) from each formula was introduced into a 100 ml 
measuring cylinder. After the initial volume was observed, the cylinder was allowed to 
keep in bulk density apparatus for tapping. The tapping was continued until no further 
change in volume was noted. 
The bulk density, and tapped density were calculated using the following 
Formulas: - 
 
 Bulk density (ρ0) = M/Vo 
Where, M = mass of the powder  
 Vo = volume of the powder  
Tapped density (ρt) = M/Vf 
Where,          M = weight of sample powder taken 
                     Vf = tapped volume 
 
 Compressibility index (Carr’s index): 
 
Compressibility index is an important measure that can be obtained from the bulk and 
tapped densities. In theory, the less compressible a material the more flow able it is. A 
material having value of less than 18 % is defined as the free flowing material. 
125 
 
                  CI = 100 (V0 - Vf) / V0 
Where, 
                    CI = Compressibility index. 
Hausner’s Ratio: 
It indicates the flow properties of the powder and is measured by the ratio of tapped 
density to the bulk density. 
 
        Hausner’s Ratio = Tapped density / Bulk density. 
 
LOSS ON DRYING:  
 
In pharmacy, the term loss on drying, commonly referred to as LOD, is an expression of 
moisture content on a wet- weight basis, which is calculated as, 
 
                    Weight of water in sample 
% LOD = -------------------------------------- 
                    Weight of the sample 
 
Method: 
 
The moisture content of substances was determined gravimetrically on a SARTORIUS 
MA-45 moisture balance  Approximately 1gm of sample was uniformly placed onto the 
sample pan and then the heating cycle was started. The percentage of moisture content 
was calculated from the weight loss of sample by heating. The instrument was allowed 
to cool between tests and triplicate test was run for each sample. 
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Tablet evaluation:
22
 
The following tests are applied on uncoated tablet. 
Appearance 
The general appearance and elegance of tablet was identified visually, which include 
tablet size, shape, color, presence or absence of odour, taste, surface texture etc. 
 
Description 
Yellow, circular, flat, beveledged uncoated tablet having a breakline on oneside and 
other side plain. 
 
Weight variation  
Weight variation test was done by weighing 20 tablets individually, calculating the 
average weight and comparing the individual tablets weight to the average. The tablets 
meet the USP test if no more than 2 tablets are outside the percentage limit and if no 
tablets differ by more than two times the percent limit. The table given below shows the 
weight variation tolerance for uncoated tablets. 
 
Weight variation tolerance for uncoated tablets: 
 
Average Weight Of Tablets (mg) Maximum Percentage Difference 
Allowed 
80 or Less 10 
80 – 250 7.5 
More Than 250 5 
Table No.40 
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Deviation was found was calculated as follows. 
Maximum deviation: 
 
                        + Ve = (WH – A) x 100 / A 
 
                       - Ve = (A – WL ) x 100 / A 
Where, 
A     = Average weight of tablets. 
 
WH = Highest weight of tablet in 20 tablets. 
 
WL = Lowest weight of tablet in 20 tablets. 
 
Thickness:  
 
The thickness of the tablets was measured using Digital Vernier Caliper. It is expressed 
in mm. Tablet thickness should be controlled within a ± 0.5 % variation of standard 
value. 
 
Hardness:  
Hardness is the crushing strength of tablets which determines the ease of handling and 
rigors of the transportation. The hardness of the tablets was measured using Erweka 
hardness tester. The instrument reads in kg / cm². 
 
Friability: 
Friability test is performed to assess the effect of friction and shocks, which may often 
cause tablets to chip or break. Roche friabilator was used for the purpose. This device 
subjects a number of tablets to the combined effect of abrasion and shock by utilizing a 
plastic chamber that revolves at 25 rpm dropping the tablets at a distance of 6 inches 
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with each revolution. Normally, a preweighed tablets sample is placed in friabilator, 
which is then operated for 100 revolutions. The tablets are then dusted and reweighed. 
Conventional compressed tablets that lose less than 0.5 to 1% of there weight are 
generally consider acceptable. 
The percentage friability was measured using the formula: 
                                 %F = {(W-Wo) / Wo} ×100 
                                       Where %F = Friability in percentage 
                                                      W = initial weight of tablets 
                                                      Wo = weight of tablets after test 
 
Disintegration time:  
 
The USP device of test disintegration uses 6 glass tubes that are 3 inches long, open at 
the top, and held against a 10-mesh screen at the bottom end of the basket rack 
assembly.  To test the disintegration time, one tablets is placed in each tube, and the 
basket rack was positioned in a 1-litre beaker of water, at 37°C±2°C, such that the 
tablets remains 2.5 cm below the surface of the liquid on there upward movement and 
descend not closer than 2.5 cm from the bottom of the beaker. A stander motor-driven 
device is used to move the basket assembly containing the tablets up and down through a 
distance of 5 to 6 cm at a frequency of 28 to 32 cycles per minutes. This test was 
performed without using perforated plastic disc. To be in compliance with the USP 
standers, the tablets must disintegrate, and all particles must pass through the 10-mesh 
screen in the time specified. It is expressed in seconds. The time taken for each tablet to 
disintegrate was recorded. 
 
. 
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Drug content: (Assay)
34
 (IN HOUSE METHOD) 
This test determines the amount of active ingredient by the method in the assay. 
Assay Method of Artemether for Formulation 
Chromatographic Condition: 
Column : C18, 150 mm x 4.6 mm, 5 u (Inertsil ODS-3 C18 is suitable) 
Detector : 210 nm 
Flow Rate : 1.5 ml / min. 
Injection Volume : 50 µl 
Column Temperature : Ambient. 
Mobile Phase: 
A mixture of Water (380 volumes) and Acetonitrile (620 volumes), mix properly, degas, 
and then filter through 0.45 um membrane filter Paper. 
Diluent: 
Mobile Phase 
Standard Preparation: 
Weight accurately 50 mg of Aretmether W.S. in 100 ml volumetric flask.  Add 60 ml 
diluents, sonicate for 10 minutes and stir for 10 minuites, make up the volume with 
diluents. 
 
Sample Preparation: 
Weigh 20 tablets and crush to powder.  Weigh accurately powder equivalent to 50 mg of 
Artermether in 100 ml volumetric flask.  Add 60 ml diluents, sonicate for 15 minutes 
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and stir for 10 minutes and make up the volume with diluents.  Filter the resulting 
solution through 0.45 um membrane filter Paper. 
Procedure: 
Separately inject 50 ul of the standard preparation in replicate and calculate RSD of 
standard area (RSD NMT 2.0%), Tailing factor (NMT 2.0), Theoretical plate NLT 1000 
and inject test solution into the chromatogram and record the chromatograph and 
measure the response for the major peaks and calculate the result by comparison. 
Calculation:    Artemether (in %) 
     Spl area Std wt.  100           Std                purity        100 
 =  -----------X-------------X--------------X----------------X------------X ---------------- X  
Average wt. 
 Avg.Std area   100  Spl wt           100  Label claim 
Assay Method of Lumefantrine for Formulation (LUMEFANTRINE) : 
Chromatographic Condition: 
Column : C18, 150 mm x 4.6 mm, 5u (Phenomenex Gemini is 
suitable) 
Detector : 380 mm 
Flow Rate  : 0.8 ml / min. 
Column Temperature : Ambient 
 
 
131 
 
Buffer Preparation: 
Take 1.5 gm of Ammonium acetate in 100o ml water; adjust pH 2.8 with dilute ortho 
phosphoric acid. 
Mobile Phase: 
A mixture of Buffer (300 volumes) and Acetonitrile (700 volumes), mix properly, degas, 
and then filter through 0.45 um membrane filter Paper. 
Diluent: 
Mobile phase 
Standard preparation: 
Weigh accurately 20 mg of Lumefantrine W.S. in 100 ml volumetric flack.  Add 60 ml 
diluents, sonicate for 10 minutes and stir for 10 minutes, make up the volume with 
diluents.  Dilute 5 ml of the resulting solution in 25 ml volumetric flask and make up 
volume with diluents. 
Sample preparation: 
Weigh 20 tablets and crush to powder.  Weigh accurately powder equivalent to 20 mg of 
Lumefantrine in 100 ml volumetric flask.  Add 60 mol diluents, sonicate for 30 minutes 
and stir for 10 minutes and make up the volume with diluents.  Take 30 ml solution for 
centrifuge, Speed 2000 RPM for 10 min, and dilute 5 ml of the resulting solution in 25 
ml volumetric flask and make up volume with diluents. 
Procedure: 
Separately inject 50 ul of the standard preparation in replicate and calculate RSD of 
standard area (RSD NMT 2.0%) and inject test solution into the chromatogram and 
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record the chromatograph and measure the response for the major peaks and calculate 
the result. 
calculation: 
Spl area Std wt.  5 100 25 Std purity 100 
=-----------X-------------X--------------X---------X----------X-----------X-----------X Average 
wt. 
Avg.Std area 100  25 Spl wt 5 100  Label claim  
In vitro dissolution study:
35
 
Dissolution parameter for Artemether 
Medium : 900ml of Water 
Apparatus : USP II (Paddle) 
Speed : 100 rpm 
Time : 180 minutes (30,60,90,120,180) min 
Temperature : 37º C ± 0.5 º C 
 
Procedure :  
Place the stated volume of dissolution medium in the vessels of the apparatus, assemble 
the apparatus and equilibrate the dissolution medium 37º C ± 0.5 º C, place one tablet in 
each of the vessels and immediate operate at specified rate after suspending the paddle.  
At the end of the specified time, withdraw the sample solution from the zone midway 
between the surface of the dissolution medium and top of the blade, not less than 1 cm 
from the vessel wall.  Filter the sample solution through 0.8 um membrane filter; discard 
first few ml of the filtrate. 
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Standard Preparation: 
Weigh accurately 40 mg of Artemether WS. In 100 ml volumetric flask, add 60 ml 
mobile phase sonicate to dissolve and make up the volume with mobile phase.  Dilute 5 
ml of the resulting solution in 100 ml volumetric flask and make up volume with 
dissolution media. 
Chromatographic Condition, Mobile phase same as assay of Artermether: 
Procedure: 
Separately inject 100 μl of the standard preparation in replicate and calculate RSD of 
standard area (RSD NMT 2.0%) and inject assay preparation into the chromatogram and 
record the chromatograph and measure the response for the major peaks and calculate 
the result. 
Calculation: Artemether (Release in %) 
Spl abs  Std wt.  5 1000     25  99           100 
=-----------X-------------X--------------X---------X----------X-----------X-----------X Average 
wt. 
Std. abs 200  25    1      5         100         Label claim 
Dissolution parameter for Lumefantrine 
Medium : 900ml of 0.1M Hydrochloric acid with 1% Benzal konium 
Chloride 
Apparatus : USP II (Paddle) 
Speed : 100 rpm 
Time : 60 minutes (10,15,30,45,60) min 
Temperature : 37º C ± 0.5 º C 
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Procedure :  
 
Place the stated volume of dissolution medium in the vessels of the apparatus, assemble 
the apparatus and equilibrate the dissolution medium to 37º C ± 0.5 º C, place one tablet 
in each of the vessels and immediate operate at specified rate after suspending the 
paddle.  At the end of the specified time, withdraw the sample solution from the zone 
midway between the surface of the dissolution medium and top of the blade, not less 
than 1 cm from the vessel wall.  Filter the sample solution through 0.8 μm membrane 
filter, discard first few ml of the filtrate.  Dilute 5 ml of the resulting solution in 25 ml 
volumetric flask and make up volume with mobile phase. 
Standard Preparation: 
Weigh accurately 22 mg of Lumefantrine WS. in 200 ml volumetric with Acetonitrile. 
Dilute 5 ml of the resulting solution in 25 ml volumetric flask and make up volume with 
dissolution media. 
Chromatographic Condition, Mobile phase same as assay of Lumfantrine: 
Procedure: 
Separately inject 100 ml of the standard preparation in replicate and calculate RSD of 
standard area (RSD NMT 2.0 %) and inject assay preparation into the chromatogram 
and record he chromatograph and measure the response for the major peaks and 
calculate the result. 
Calculation: Lumefantrine (Release in %) 
Spl abs  Std wt.  5    1000         99.2           100 
=-----------X-------------X--------------X---------X----------X-----------X Average wt. 
Std. abs 100  100       1          100      Label claim 
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Similarity Factor and Difference Factor Calculation (In house method) 
The similarity factor (f2) was defined by CDER, FDA, and EMEA as the ―logarithmic  
reciprocal square root transformation of one plus the mean squared difference in percent 
dissolved between the test and refrence release profiles. 
Dissimilarity or difference factor (f1) describes the relative error between two 
dissolution profiles. It approximates the percent error between the curves. The percent 
error is zero when the test and reference release profiles are identical and increases 
proportionally with the dissimilarity between the two profiles.There are several methods 
for dissolution profile comparison. f2   is the simplest  among those methods. Moore & 
Flanner proposed a model independent mathematical approach to compare the 
dissolution profile using two factors f1  & f2. 
 f1  = { [  t=1 nRt  – Tt   ] / [  t=1 n Rt ] } . 100           eq (1) 
 f2  = 50. Log { [1 + (1/n)  t=1 n (Rt - Tt ) 2  ] –0.5 . 100}       eq (2) 
where ‘Rt’ and ‘Tt’ are the cumulative percentage dissolved at each of the selected n  
time point of the reference & test product respectively. The factor f1  is proportional to 
the average difference between the two profiles, where as factor f2  is inversely 
proportional to the averaged squared difference between the two profiles, with emphasis 
on the larger difference among all the  time points. The similarity factor f2  and its 
significance is shown in the following. 
 
Similarity factor f2 and its significance 
1. <50 Test and reference profiles are dissimilar. 
2. 50 -100 Test and reference profiles are similar. 
3. 100 Test and reference profiles are identical. 
4. >100 The equation yields a negative value. 
136 
 
Table No.41 
Similarity factor (f2)and dissimilar factors (f1). The test and reference release profiles of 
artemether and lumefantrine Were performed and results was found. 
Observation for different trial batches: 
Physical characterization of blends of all Trial batches. 
Trial Bulk Density 
( g / cc) 
Tapped Density 
( g / cc) 
%Compressibility 
index 
Hausner’s 
ratio 
F1 0.5089 0.6694 23.98 1.32 
F2 0.5069 0.7060 28.21 1.39 
F3 0.5133 0.6673 23.08 1.30 
F4 0.5091 0.7202 29.33 1.41 
Table No.42 
Particle size distribution of all Trial batches: 
Sieve No. 
Percentage Retained 
F1 F2 F3 F4 
30# 7.69 9.32 7.048 9.73 
40# 38.69 43.76 39.013 43.65 
60# 19.04 20.61 19.53 20.98 
100# 10.36 12.89 10.06 11.98 
Base pan 24.22 13.42 29.44 13.66 
Table No.43 
Total amount of blend = 25 g. 
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Physical characterization of uncoated Artemther and Lumefantrine trial batches: 
Trial Average 
weight (g) 
Thickness 
(mm) 
Diameter 
(mm) 
Hardness 
(Kg / cm
2
) 
Friability 
(% W/W) 
DT 
F1 2.405 3.1 9.0 5 0.21 45 sec 
F2 2.400 3.2 9.0 4.5 0.11 2 min 20 
sec 
F3 2.423 3.0 9.1 5 0.07 2 min 40 
sec 
F4 2.388 3.1 9.1 5 0.16 3 min 18 
sec 
Table No.44 
Uniformity of Weight Test for Tablets – Trial F3 
Sl.No. Weight of tablet (mg) Deviation % Deviation 
1 0.2448 0.0025 1.0318 
2 0.2433 0.0010 0.4127 
3 0.2435 0.0012 0.4953 
4 0.2418 -0.0005 -0.2064 
5 0.2439 0.0016 0.6603 
6 0.2434 0.0011 0.4540 
7 0.2394 -0.0029 -1.1969 
8 0.2421 -0.0002 -0.0825 
9 0.2418 -0.0005 -0.2064 
10 0.2398 -0.0025 -1.0318 
11 0.2427 0.0004 0.1651 
12 0.2427 0.0004 0.1651 
13 0.2433 0.0010 0.4127 
14 0.2429 0.0006 0.2476 
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15 0.2425 0.0002 0.0825 
16 0.2404 -0.0019 -0.7842 
17 0.2416 -0.0007 -0.2889 
18 0.2439 0.0016 0.6603 
19 0.2421 -0.0002 -0.0825 
20 0.2401 -0.0022 -0.9080 
Table No.45 
Wt. Of 20 tabs 
4.8457g 
Average Wt. Of 1 tab 0.2423g 
 
All the tablets were passed the Uniformity of Weight test. The tablets had average 
weights ranging from 0.24 to 0.36g 
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Dissolution profile – F1(A) 
 
  
 
MEDOPHARM PRIVATE LIMITED, GUDUVANCHERY 
R&D ANALYTICAL DEPARTMENT 
DIFFERENCE FACTOR (F1) & SIMILARITY FACTOR (F2) 
Product name F 1 
Artemether & Lumefantrine Tablets 
20+120mg 
Batch no. /Lot no. F 1 Manufactrer Medopharm PVT. LTD 
Mfg.date   A.R. No. ARD-2368 
Exp.date 
  
Date of 
Analysis   
 
Innovator / Reference 
 
Coartem 
Artemether & Lumefantrine Tablets 
20+120mg 
 
Batch no. /Lot no. 
 
F2772 
Manufactrer Novartis 
Mfg.date 
Feb-12 
Date of 
Analysis   
Exp.date Jan-14   
Dissolution parameter : 
   
  
  
 
Medium : 1000ml of  water.   
BY HPLC Apparatus : USP II (Paddle)   
ARTEMETHER 
Speed : 100 
RPM 
 
  
  
 
Time interval :  30min., 60min., 90min.,120min. & 180min. 
Time point Coartem F1 Rt-Tt (Rt-Tt)² |Rt-Tt| 
0 0.00 0.00 0.00  0.00 0.00 
30 45.67 38.42 3.64  52.56 7.25 
60 62.30 56.89 4.20  29.27 5.41 
90 72.93 68.25 1.22  21.90 4.68 
120 80.18 74.86  -2.60 28.30 5.32 
180 89.16 81.92 -7.15  52.42 7.24 
SUM 350.24     184.45 29.90 
Number of Time points or intervals[Excluding zero ] 5 
Difference Factor - F1[Acceptance Criteria : 0 - 15 ] 8.54 
Similarity Factor - F2[Acceptance Criteria : 50 - 100 ] 60.54 
Table – 46 
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Dissolution profile – F1(L) 
 
  
 
MEDOPHARM PRIVATE LIMITED, GUDUVANCHERY 
R&D ANALYTICAL DEPARTMENT 
DIFFERENCE FACTOR (F1) & SIMILARITY FACTOR (F2) 
Product name F 1 Artemether & Lumefantrine Tablets 20+120mg 
Batch no. /Lot no. F 1 Manufactrer Medopharm PVT. LTD 
Mfg.date   A.R. No. ARD-2363 
Exp.date   Date of Report   
 
Innovator / Reference 
 
Coartem Artemether & Lumefantrine Tablets 20+120mg 
 
Batch no. /Lot no. 
 
F2772 
Manufactrer Novartis 
Mfg.date Feb-12 Date of Report   
Exp.date Jan-14   
Dissolution parameter : 
   
  
  
 
Medium : 1000ml of 0.1 M HCl with 1% 
BKC.   
BY UV Apparatus : USP II (Paddle)   
LUMEFANTRINE Speed : 75 RPM 
 
  
  
 
Time interval :  10min., 15min., 30min., 45min. & 60min. 
Time point Coartem F 1 Rt-Tt (Rt-Tt)² |Rt-Tt| 
0 0.00 0.00 0.00 0.00 0.00 
10 54.50 45.59 8.91 79.39 8.91 
15 62.87 55.56 7.31 53.44 7.31 
30 77.05 70.90 6.15 37.82 6.15 
45 83.15 77.99 5.16 26.63 5.16 
60 85.89 83.11 2.78 7.73 2.78 
SUM 363.46     205.00 30.31 
Number of Time points or intervals[Excluding zero ] 5 
Difference Factor - F1[Acceptance Criteria : 0 - 15 ] 8.34 
Similarity Factor - F2[Acceptance Criteria : 50 - 100 ] 59.42 
Table no-47 
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Dissolution profile – F1(A&L) (Graphical report) 
            
 
  
 
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
CONCLUSION : The difference factor (F1) & Similarity factor (F2) 
                             not Similar when compared with reference product 
  
    
  
 
  
 
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
CONCLUSION : The difference factor (F1) & Similarity factor (F2) 
                             not similar when compared with reference product 
            
Fig no- 11 
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Dissolution profile – F2(A) 
 
  
 
MEDOPHARM PRIVATE LIMITED, GUDUVANCHERY 
R&D ANALYTICAL DEPARTMENT 
DIFFERENCE FACTOR (F1) & SIMILARITY FACTOR (F2) 
Product name F 2 
Artemether & Lumefantrine Tablets 
20+120mg 
Batch no. /Lot no. F 2 Manufactrer Medopharm PVT. LTD 
Mfg.date   A.R. No. ARD-2368 
Exp.date   Date of Analysis   
 
Innovator / Reference 
 
Coartem 
Artemether & Lumefantrine Tablets 
20+120mg 
 
Batch no. /Lot no. 
 
F2772 
Manufactrer Novartis 
Mfg.date Feb-12 Date of Analysis   
Exp.date Jan-14   
Dissolution parameter : 
   
  
  
 
Medium : 1000ml of  water.   
BY HPLC Apparatus : USP II (Paddle)   
ARTEMETHER 
Speed : 100 
RPM 
 
  
  
 
Time interval :  30min., 60min., 90min.,120min. & 180min. 
Time point Coartem F 2 Rt-Tt (Rt-Tt)² |Rt-Tt| 
0 0.00 0.00 0.00 0.00 0.00 
30 45.67 48.68 4.01 9.06 3.01 
60 62.30 68.30 -2.88 36.00 6.00 
90 72.93 77.72 -7.17 22.94 4.79 
120 80.18 83.06 0.07 8.29 2.88 
180 89.16 89.08 0.08 0.01 0.08 
SUM 350.24     76.30 16.76 
Number of Time points or intervals[Excluding zero ] 5 
Difference Factor - F1[Acceptance Criteria : 0 - 15 ] 4.79 
Similarity Factor - F2[Acceptance Criteria : 50 - 100 ] 69.72 
Table no – 48 
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Dissolution profile – F2(L) 
 
  
 
MEDOPHARM PRIVATE LIMITED, GUDUVANCHERY 
R&D ANALYTICAL DEPARTMENT 
DIFFERENCE FACTOR (F1) & SIMILARITY FACTOR (F2) 
Product name F 2 Artemether & Lumefantrine Tablets 20+120mg 
Batch no. /Lot no. F 2 Manufactrer Medopharm PVT. LTD 
Mfg.date   A.R. No. ARD-2314 
Exp.date   Date of Report   
 
Innovator / Reference 
 
Coartem Artemether & Lumefantrine Tablets 20+120mg 
 
Batch no. /Lot no. 
 
F2772 
Manufactrer Novartis 
Mfg.date Feb-12 Date of Report   
Exp.date Jan-14   
Dissolution parameter : 
   
  
  
 
Medium : 1000ml of 0.1 M HCl with 
1% BKC.   
BY UV Apparatus : USP II (Paddle)   
LUMEFANTRINE 
Speed : 75 
RPM 
 
  
  
 
Time interval :  10min., 15min., 30min., 45min. & 60min. 
Time point Coartem F 2 Rt-Tt (Rt-Tt)² |Rt-Tt| 
0 0.00 0.00 0.00 0.00 0.00 
10 54.50 37.95 16.55 273.90 16.55 
15 62.87 45.77 17.10 292.41 17.10 
30 77.05 61.06 15.99 255.68 15.99 
45 83.15 72.89 10.26 105.27 10.26 
60 85.89 79.10 6.79 46.10 6.79 
SUM 363.46     973.36 66.69 
Number of Time points or intervals[Excluding zero ] 5 
Difference Factor - F1[Acceptance Criteria : 0 - 15 ] 18.35 
Similarity Factor - F2[Acceptance Criteria : 50 - 100 ] 42.71 
 
Table no- 49 
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Dissolution profile – F2 (A&L)(Graphical report) 
            
 
  
 
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
CONCLUSION : The difference factor (F1) & Similarity factor (F2) not 
                           similar when compared with reference product                           
 
  
 
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
CONCLUSION : The difference factor (F1) & Similarity factor (F2)  
                            not similar when compared with reference product 
            
Fig no-12 
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          Dissolution profile – F3(A) 
 
 MEDOPHARM PRIVATE LIMITED, GUDUVANCHERY 
  R&D ANALYTICAL DEPARTMENT 
DIFFERENCE FACTOR (F1) & SIMILARITY FACTOR (F2) 
Product name F 3   
Artemether & Lumefantrine 
Tablets 20+120mg 
  
Batch no. /Lot no.   F-3   
Manufactrer 
Medopharm 
PVT. LTD 
Mfg.date   Dec-12   A.R. No. ARD-2314 
Exp.date   Nov-14   Date of Analysis   
 
Innovator / Reference 
 
Coartem   
Artemether & Lumefantrine 
Tablets 20+120mg 
  
 
Batch no. /Lot no. 
 
 F2772   
Manufactrer Novartis 
Mfg.date  Feb-12   Date of Analysis   
Exp.date Jan-14       
Dissolution parameter : 
   
  
  
 
Medium : 
1000ml of  
water. 
 
  
BY HPLC 
Apparatus : USP 
II (Paddle) 
 
  
ARTEMETHER 
Speed : 100 
RPM 
 
  
  
 
Time interval :  30min., 60min., 90min.,120min. & 180min. 
Time point Coartem F 3 Rt-Tt (Rt-Tt)² |Rt-Tt| 
0 0.00 0.00 0.00 0.00 0.00 
30 40.52 36.46 4.06 16.48 4.06 
60 56.10 63.27 -7.17 51.41 7.17 
90 66.24 78.04 -11.80 139.24 11.80 
120 74.35 85.85 -11.50 132.25 11.50 
180 81.53 93.85 -12.32 151.78 12.32 
SUM 318.74   491.16 46.85 
Number of Time points or intervals[Excluding zero ] 
                                                                                                                                                    5 
Difference Factor - F1[Acceptance Criteria : 0 - 15  
                                                                                                                                                  14.70 
Similarity Factor - F2[Acceptance Criteria : 50 - 100 ] 
                                                                                                                                                  50.08 
      
     Table no-50 
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    Dissolution profile – F3(L) 
 
  
 
MEDOPHARM PRIVATE LIMITED, GUDUVANCHERY 
R&D ANALYTICAL DEPARTMENT 
DIFFERENCE FACTOR (F1) & SIMILARITY FACTOR (F2) 
Product name F 3 
Artemether & Lumefantrine Tablets 
20+120mg 
Batch no. /Lot no.  F3 Manufactrer   
Mfg.date Dec-12 A.R. No. ARD-2272 
Exp.date   Date of Analysis   
 
Innovator / Reference 
 
Coartem 
Artemether & Lumefantrine Tablets 
20+120mg 
 
Batch no. /Lot no. 
 
F2772 
Manufactrer Novartis 
Mfg.date Feb-12 Date of Analysis   
Exp.date Jan-14   
Dissolution parameter : 
   
  
  
 
Medium : 1000ml of 0.1 M HCl with 1% BKC.   
BY UV Apparatus : USP II (Paddle)   
LUMEFANTRINE Speed : 75 RPM 
 
  
  
 
Time interval :  10min., 15min., 30min., 45min. 
& 60min.   
Time point Coartem F3 Rt-Tt (Rt-Tt)² |Rt-Tt| 
0 0.00 0.00 0.00 0.00 0.00 
10 54.50 50.86 3.64 13.25 3.64 
15 62.87 58.67 4.20 17.64 4.20 
30 77.05 75.91 1.14 1.30 1.14 
45 83.15 85.76 -2.61 6.81 2.61 
60 85.89 92.04 -6.15 37.82 6.15 
SUM 363.46     76.82 17.74 
Number of Time points or intervals[Excluding zero ] 5 
Difference Factor - F1[Acceptance Criteria : 0 - 15 ] 4.88 
Similarity Factor - F2[Acceptance Criteria : 50 - 100 ] 69.65 
Table no -51 
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Dissolution profile – F3 (A&L)(Graphical report) 
 
  
 
          
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
CONCLUSION : The difference factor (F1) & Similarity factor (F2)    
                             similar when compared with reference product   
 
  
 
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
CONCLUSION : The difference factor (F1) & Similarity factor (F2)    
                             similar when compared with reference product   
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   Dissolution profile – F4(A) 
 
  
 
MEDOPHARM PRIVATE LIMITED, GUDUVANCHERY 
R&D ANALYTICAL DEPARTMENT 
DIFFERENCE FACTOR (F1) & SIMILARITY FACTOR (F2) 
Product name F 4 Artemether & Lumefantrine Tablets 20+120mg 
Batch no. /Lot no. F 4 Manufactrer Medopharm PVT. LTD 
Mfg.date   A.R. No. ARD2367 
Exp.date   Date of Report   
 
Innovator / Reference 
 
Coartem Artemether & Lumefantrine Tablets 20+120mg 
 
Batch no. /Lot no. 
 
F2772 
Manufactrer Novartis 
Mfg.date Feb-12 Date of Report   
Exp.date Jan-14   
Dissolution parameter : 
   
  
  
 
Medium : 1000ml of  water.   
BY HPLC Apparatus : USP II (Paddle)   
ARTEMETHER 
Speed : 100 
RPM 
 
  
  
 
Time interval :  30min., 60min., 90min.,120min. & 180min. 
Time point Coartem F 4 Rt-Tt (Rt-Tt)² |Rt-Tt| 
0 0.00 0.00 0.00 0.00 0.00 
30 38.49 37.16 1.33 1.77 1.33 
60 54.61 53.16 1.45 2.10 1.45 
90 63.19 58.44 4.75 22.56 4.75 
120 70.17 67.28 2.89 8.35 2.89 
180 79.58 74.66 4.92 24.21 4.92 
SUM 306.04     58.99 15.34 
Number of Time points or intervals[Excluding zero ] 5 
Difference Factor - F1[Acceptance Criteria : 0 - 15 ] 5.01 
Similarity Factor - F2[Acceptance Criteria : 50 - 100 ] 72.32 
Table no – 52 
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   Dissolution profile – F4(L) 
 
  
 
MEDOPHARM PRIVATE LIMITED, GUDUVANCHERY 
R&D ANALYTICAL DEPARTMENT 
DIFFERENCE FACTOR (F1) & SIMILARITY FACTOR (F2) 
Product name F 4 Artemether & Lumefantrine Tablets 20+120mg 
Batch no. /Lot no. F 4 Manufactrer Medopharm PVT. LTD 
Mfg.date   A.R. No. ARD-2314 
Exp.date   Date of Report   
 
Innovator / Reference 
 
Coartem Artemether & Lumefantrine Tablets 20+120mg 
 
Batch no. /Lot no. 
 
F2772 
Manufactrer Novartis 
Mfg.date Feb-12 Date of Report   
Exp.date Jan-14   
Dissolution parameter : 
   
  
  
 
Medium : 1000ml of 0.1 M HCl with 1% 
BKC.   
BY UV Apparatus : USP II (Paddle)   
LUMEFANTRINE Speed : 75 RPM 
 
  
  
 
Time interval :  10min., 15min., 30min., 45min. & 60min. 
Time point Coartem F 4 Rt-Tt (Rt-Tt)² |Rt-Tt| 
0 0.00 0.00 0.00 0.00 0.00 
10 54.50 38.54 15.96 254.72 15.96 
15 62.87 46.54 16.33 266.67 16.33 
30 77.05 62.38 14.67 215.21 14.67 
45 83.15 73.74 9.41 88.55 9.41 
60 85.89 80.72 5.17 26.73 5.17 
SUM 363.46     851.88 61.54 
Number of Time points or intervals[Excluding zero ] 5 
Difference Factor - F1[Acceptance Criteria : 0 - 15 ] 16.93 
Similarity Factor - F2[Acceptance Criteria : 50 - 100 ] 44.15 
Table no -53 
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Dissolution profile – F4 (A&L)(Graphical report) 
            
 
  
 
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
  
    
  
CONCLUSION : The difference factor (F1) & Similarity factor (F2)   
                              not similar when compared with reference product   
  
    
  
 
  
 
    
  
  
    
  
  
    
  
  
    
  
  
   
   
  
   
   
  
   
   
  
   
   
    
   
  
    
  
  
    
  
  
    
  
  
    
  
CONCLUSION : The difference factor (F1) & Similarity factor (F2)   
          Not similar when compared with reference product   
Fig no – 14 
 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
0 20 40 60 80 100 120 140 160 180 200 
%
 R
el
ea
se
 
Time in min. 
Comparision Dissolution 
Coartem F 4 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
0 5 10 15 20 25 30 35 40 45 50 
%
 R
el
ea
se
 
Time in min. 
Comparision Dissolution 
Coartem F 4 
151 
 
Assay parameter-F1(A) 
MEDOPHARM PRIVATE LIMITED,GUDUVANCHERY 
R&D Analytical Department 
Product Name:Artemether(20)+Lumefantrine(120mg) Tablets.   
Batch No.: F1 
  
   
  
Assay :Content of Artemether 
 
project data   
  
   
  
Standard Preparation: 51.1mg -----> 100ml@ Mobile phase 
Test Preparation : 828.2mg tabs powder. ---------> 100ml@Mobile phase 
  
   
  
  Name of Std % of purity 
 
  
  Artemether 99.22 
Average wt of tablet 
330.9mg 
  
   
  
  Artemether std area Artemether spl area Assay in mg Assay in % 
  706730 669650 
 
  
  684719 671836 
 
  
  683506 
  
  
  682443 
 
19.75 98.7 
  683080 
  
  
    
  
  
Average 688096 670743 
 
  
Stdev 10450 
  
  
RSD 1.52 
  
  
Table no- 54 
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Assay parameter-F1(L) 
MEDOPHARM PRIVATE LIMITED,GUDUVANCHERY 
R&D Analytical Department 
Product Name: Artemether + Lumefantrine (20+120)mg Tablets 
Batch No.: F1 
  
   
  
Assay :Content of 
Lumefantrine 
  
  
  
   
  
Standard Preparation: 20.0mg -----> 100ml, 5ml------->25ml@ Mobile phase 
Test Preparation : 48.2mg tabs powder. ---------> 100ml,5------->25ml @Mobile phase. 
  
   
  
Name of Std % of purity Average wt. of Tablet: 241.7mg 
Lumefantrine 99.0     
  
   
  
   Std area  Spl area Assay in mg Assay in % 
  1115146 1323473 
 
  
  1112896 1323730 
 
  
  1113794 
  
  
  1114558 
 
118.16 98.5 
  1116275 
  
  
    
  
  
Average 1114534 1323602 
 
  
Stdev 1288 
  
  
RSD 0.12 
  
  
Table no-55 
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Assay parameter-F1(A) 
MEDOPHARM PRIVATE LIMITED,GUDUVANCHERY 
R&D Analytical Department 
Product Name:Artemether(20)+Lumefantrine(120mg) Tablets.       
Batch No.: F2 
  
     
  
Assay :Content of Artemether 
    
  
  
     
  
Standard Preparation: 51.1mg -----> 100ml@ Mobile phase 
Test Preparation : 915.2mg tabs powder. ---------> 100ml@Mobile phase 
  
    
  
Name of Std % of purity 
  
  
Artemether 99.22 
Average wt of tablet 
330.9mg    
  
     
  
  
Artemether std 
area 
Artemether spl 
area 
Assay in 
mg 
Assay in 
% 
 
  
  706730 741646 
   
  
  684719 742166 
   
  
  683506 
    
  
  682443 
 
19.77 98.8 
 
  
  683080 
    
  
    
    
  
Average 688096 741906 
   
  
Stdev 10450 
    
  
RSD 1.52 
    
  
Table no -56 
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Assay parameter-F2(L) 
MEDOPHARM PRIVATE LIMITED,GUDUVANCHERY 
R&D Analytical Department 
Product Name: Artemether + Lumefantrine (20+120)mg Tablets   
Batch No.: F2  
  
     
  
Assay :Content of 
Lumefantrine 
    
  
  
     
  
Standard Preparation: 20.1mg -----> 100ml, 5ml------->25ml@ Mobile phase 
Test Preparation : 44.5mg tabs powder. ---------> 100ml,5------->25ml @Mobile phase. 
  
    
  
Name of Std % of purity Average wt. of Tablet: 240.4mg   
Lumefantrine 99.0 
 
  
  
     
  
   Std area  Spl area Assay in mg Assay in % 
 
  
  1044466 1140725 
   
  
  1040008 1138185 
   
  
  1039717 
    
  
  1046149 
 
117.55 98.0 
 
  
  1039795 
    
  
  
     
  
Average 1042027 1139455 
   
  
Stdev 3055 
    
  
RSD 0.29 
    
  
Table no-57 
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Assay parameter-F3(A) 
MEDOPHARM PRIVATE LIMITED,GUDUVANCHERY 
R&D Analytical Department 
Product Name:Artemether(20)+Lumefantrine(120mg) Tablets. 
Batch No.:F-3 
  
    
  
Assay :Content of Artemether 
  
  
  
    
  
Standard Preparation: 50.7mg -----> 100ml@ Mobile phase 
Test Preparation : 604.6mg tabs powder. ---------> 100ml@Mobile phase 
  
    
Name of Std % of purity 
  
Artemether 99.22 Average wt of tablet 241.7mg   
  
    
  
Artemether std 
area 
Artemether spl area Assay in mg Assay in % 
  
  Apr-13 Mar-90 
  
  
  Jan-13 Oct-83 
  
  
  Feb-12 
   
  
  Nov-11 
 
19.84 99.2   
  Sep-17 
   
  
  
    
  
Average 735457 725735 
  
  
Stdev 859 
   
  
RSD 0.12 
   
  
 
Table no-58 
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Assay parameter-F3 (L) 
MEDOPHARM PRIVATE LIMITED,GUDUVANCHERY 
R&D Analytical Department 
Product Name:Artemether(20)+ Lumefantrine(120) tablets     
Batch No.: F-3 
  
    
  
Assay :Content of Lumefantrine 
  
  
  
    
  
Standard Preparation: 20.2mg -----> 100ml, 5ml------->25ml@ Mobile phase 
Test Preparation : 55.0mg tabs powder. ---------> 100ml,5------->25ml @Mobile 
phase. 
  
    
Name of Std % of purity Average wt. of Tablet: 333.9mg 
Lumefantrine 99.0 
 
  
    
  
   Std area  Spl area Assay in mg Assay in %   
  Nov-71 Jan-19 
  
  
  Oct-69 May-24 
  
  
  Jun-73 
   
  
  
  
119.43 99.5   
  
    
  
Average 1121925 1103650 
  
  
Stdev 681 
   
  
RSD 0.06 
   
  
Table no-59 
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Assay parameter-F4 (A) 
MEDOPHARM PRIVATE LIMITED,GUDUVANCHERY 
R&D Analytical Department 
Product Name:Artemether(20)+Lumefantrine(120mg) Tablets.   
Batch No.: F 4 
  
    
  
Assay :Content of 
Artemether 
   
  
  
    
  
Standard Preparation: 50.5mg -----> 100ml@ Mobile phase 
Test Preparation : 685.3mg tabs powder. ---------> 100ml@Mobile phase 
  
    
Name of Std % of purity 
  
Artemether 99.22 Average wt of tablet 240.1mg 
  
    
  
Artemether std area Artemether spl area Assay in mg Assay in %   
  2E+06 1479891 
  
  
  2E+06 1476767 
  
  
  2E+06 
   
  
  2E+06 
 
19.68 98.4   
  2E+06 
   
  
  2E+06 
   
  
  
    
  
Average ###### 1478329 
  
  
Stdev 614 
   
  
RSD 0.04 
   
  
Table no-60 
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Assay parameter-F4 (L) 
MEDOPHARM PRIVATE LIMITED,GUDUVANCHERY 
R&D Analytical Department 
Product Name: Artemether + Lumefantrine (20+120)mg Tablets   
Batch No.: F4 
  
    
  
Assay :Content of 
Lumefantrine 
   
  
  
    
  
Standard Preparation: 20.0mg -----> 100ml, 5ml------->25ml@ Mobile phase 
Test Preparation : 40.2mg tabs powder. ---------> 100ml,5------->25ml @Mobile phase. 
  
    
Name of Std % of purity Average wt. of Tablet: 241.7mg 
Lumefantrine 99.0 
 
  
    
  
   Std area  Spl area Assay in mg Assay in %   
  1E+06 1095095 
  
  
  1E+06 1096615 
  
  
  1E+06 
   
  
  1E+06 
 
117.05 97.5   
  1E+06 
   
  
  
    
  
Average ###### 1095855 
  
  
Stdev 1288 
   
  
RSD 0.12 
   
  
Table no – 61 
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Assay parameter-COARTEM (A)  
MEDOPHARM PRIVATE LIMITED,GUDUVANCHERY 
R&D Analytical Department 
Product Name:Coartem  Tablets (20+120)mg   
Batch No.: F2772 
  
    
  
Assay :Content of Artemether 
   
  
  
    
  
Standard Preparation: 50.4mg -----> 100ml@ Mobile phase 
Test Preparation : 605.7mg tabs powder. ---------> 100ml@Mobile phase 
  
    
Name of Std % of purity 
  
Artemether 99.22 Average wt of tablet 241.9mg 
  
    
  
  Artemether std area Artemether spl area Assay in mg Assay in %   
  720847 689486 
  
  
  719376 690339 
  
  
  720388 
   
  
  718979 
 
19.15 95.7   
  720025 
   
  
  718091 
   
  
Average 719618 689913 
  
  
Stdev 1007 
   
  
RSD 0.14 
   
  
Table no – 62 
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Assay parameter-COARTEM (L)  
MEDOPHARM PRIVATE LIMITED,GUDUVANCHERY 
R&D Analytical Department 
Product Name: Coartem 20/120 Tablets (Novartis).   
Batch No.: F2772 
  
    
  
Assay :Content of Lumefantrine 
 
  
  
    
  
Standard Preparation: 20.5mg -----> 100ml, 5ml------->25ml@ Mobile phase 
Test Preparation : 43.1mg tabs powder. ---------> 100ml,5------->25ml @Mobile phase. 
  
    
Name of Std % of purity Average wt. of Tablet: 238.4mg 
Lumefantrine 99.0 
 
  
    
  
   Std area  Spl area Assay in mg Assay in %   
  1082861 1101175 
  
  
  1084065 1098222 
  
  
  1083031 
   
  
  1082984 
 
114.02 95.0   
  1081957 
   
  
  
    
  
  1081596 
   
  
Average 1082749 1099699 
  
  
Stdev 876 
   
  
RSD 0.08 
   
  
Table no - 63 
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Fig.No.15 
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Fig.No.16 
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Fig.No.17 
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Fig.No.18 
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FTIR OF CCS 
 
 
 
Fig No.19 
FTIR OF IPA 
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FTIR OF MCC 
 
Fig No.20 
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STABILITY STUDY
56,57,58
 
All over view 
1. Purpose 
Stability studies are an integral part of the drug development program and are one of the 
most important areas in the registration of Pharma products. The purpose of stability 
testing is to provide evidence on how the quality of a drug substance or drug product 
varies with time under the influence of a variety of environmental factors such as 
temperature, humidity and light and enables recommended storage conditions, re-test 
periods and shelf lives to be established. Stability assessment started with studies on the 
substance to determine degradation products and degradation pathway. On the ICH 
Harmonized Tripartite Guidelines on Stability testing of New Drug substances and 
products, fundamental recommendations are summarized. According to the ICH 
guideline, long term (12 months) and accelerated stability studies (at least 6 months) 
have to be carried out. 
2) Storage Conditions  
In general, a drug product should be evaluated under storage conditions (with 
appropriate tolerances) that test its thermal stability and, if applicable, its sensitivity to 
moisture or potential for solvent loss. In general cases, the study done was shown by the 
below Table. 
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Stability Study (General case): 
 
Study Storage condition 
Minimum time period 
covered by Data at 
submission 
Long term 25 ± 2°C 60 ± 5 % 
RH 
or 
30 ± 2°C 65 ± 5 % 
RH 
12 months 
Intermediate 30 ± 2°C 65 ± 5 
%RH 
6 months 
Accelerated 40 ± 2°C and 75 ± 5 % RH 6 months 
Table No.63 
The stability of drug release from Artemether and Lumfantrine tablets developed in this 
investigation was studied under varying storage conditions. These tablets was later 
packed in the screw capped bottles and stored at room temperature 
i)  25 ± 2°C / 60 ± 5 % RH 
ii) 40 ± 2°C/ 75 ± 5% RH 
 
All the products were stored for 3 months. After the storage period the release of 
Artemether and Lumefantrine from the stored product was studied. It is up to the 
± 5% RH or 3 -term 
condition, there is no intermediate condition. If long term studies are conducted at 25 ± 
at the accelerated storage condition, additional testing at the intermediate storage 
condition should be conducted and evaluated against significant change criteria.  
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For drug products packaged in impermeable containers (Aluminum tubes), semi 
permeable container (LDPE pouches, bottles etc), drug products intended for storage in 
a refrigerator, in a freezer and below –20°C, the study, storage condition and minimum 
time period covered by data at submission, are different not like as in general case. 
Testing Frequency 
For long term studies frequency of testing should be sufficient to establish the stability 
profile of the drug product. For products with a proposed shelf life of at least 12 months, 
the frequency of testing at the long term storage condition should normally be every 3 
months over the first year, every 6 months over the second year and annually thereafter 
through the proposed shelf life. At the accelerated storage condition, a minimum of three 
time points, including the initial and final time points (e.g. 0, 3 and 6 months), form a 6- 
month study is recommended. When testing at the intermediate storage condition is 
called for as a result of significant change at the accelerated storage condition, a 
minimum of four time points including the initial and final time points (e.g. 0, 6, 9, 12 
months) form a 12 month study is recommended. 
 
Joel Davis test 
 
According to Joel Davis Test, if the product holds up for 3 months under accelerated 
condition i.e. 40°C and 75% RH (chemical stability, dissolution, physical 
characteristics), then in an ANDA, the generic company will be given a two year 
expiration date but must follow up with real time data to substantiate the dating. The 
method is however, also used by ethical companies in the development of new drug 
entities. If the product does not pass the Joel Davis test, then conventional stability 
testing at room temp for prolonged periods (eighteen months) must accompany the NDA 
or the ANDA to satisfy the stability requirements of the submission. 
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Generally Acceptable Design considerations for Tablets: 
 
Tablets: 
A stability study should include tests for the following characteristics of the tablet: 
Appearance, friability, hardness, color, odor, moisture, strength and dissolution. 
. 
Procedure 
 
Artemether and Lumefanrine tablets were exposed at 40°C / 75 % RH and Normal room 
temperature at 30ºC / 65 % RH for 1 month. 
 
The tablets were withdrawn for analysis of the following parameters: 
 
 Color 
 Moisture content 
 Dissolution 
 Assay 
 
Stability Results of Artemether and Lumefantrine tablets (Batch No. F3  ) Blister 
pack: 
 
 
Condition  
Period 
(month) 
Color  Avg. Wt 
(mg) 
Hardness 
(kg / cm
2
) 
Moisture 
conent 
Assay 
(%) 
40ºC / 
75% RH 
1 Yellow 240 5 0.03% 99.32 
Table No.64 
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Dissolution Profile of Artemether and Lumefantrine Tablets  
(Batch No.F3) Blister Pack 
 
% Drug Release 
Time interval 30 min 60 min 90 min 120 min 180 min 
Artemether 46.85 69.98 83.56 88.36 95.30 
Time interval 10 min 15 min 30 min 45 min 60 min 
Lumefantrine 50.86 58.67 75.91 85.76 92.04 
 
Table No.65 
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Dissolution Profile Stability Batch F3 (Blister Pack) 
 
            
 
 
 
 
     Table No.66 
0 
20 
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60 
80 
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120 
0 min 30 min 60 min 90 min 120 min 180 min 
Artemether 
Artemether 
0 
20 
40 
60 
80 
100 
0 min 10 min 15 min 30 min 45 min 60 min 
Lumefantrine 
Lumefantrine 
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8.RESULTS AND DISCUSSION 
Recent advances in oral drug delivery system aims to enhance safety and efficacy of 
drug molecules by formulating a convenient dosage form for administration and to 
achieve better patient compliance. 
 In the present research work an attempt was made to formulae oral fixed dose 
combination tablets using excipients of varying the concentration by wet granulation 
technique. 
The API was subjected to preformulation study, which encompasses the “Accelerated 
drug excipient compatibility study”, and the results obtained with selected excipients 
showed good compatibility with API. 
In the successful tablet formulation the selected tablets were studied for their quality 
control test via Appearance, Thickness, Hardness, Weight variation, and Disintegration 
time and in- vitro dissolution study, and Assay. 
From the result obtained following points can be summarized. 
1.  Organoleptic characteristics of pure Artemether showed that the drug is white 
crystalline in nature, odourless and slightly bitter in taste. Lumefanttrine showed 
that the drug is yellowish powder, amorphous in nature, odourless and bitter in 
taste (table. 26 ) 
 
2. From the Compressibility index & Hausner’s ratio values it is concluded that the 
pure drug Artemether and Lumefantrine is having very, very poor flow 
properties. (table.34 ) 
 
3. Sieve analysis of pure Artemether shows that, all particles are not completely 
passed through 20# (table.30 ) 
180 
 
Sieve analysis of pure Lumefantrine shows that, all particles are not completely 
passed through 20# (table.31 ) 
 
4. Drug-Excipients Compatibility study is initiated in order to confirm that the drug 
and excipent does not have any incompatibility. (table.35 & figure.15 – 20. ) 
 
5. IR spectra for drug, and powdered tablets were recorded in a Fourier transform 
infrared spectrophotometer with KBr pellets.  From the peaks obtained, no extra 
peaks were seen, so all excipients are found to be compatible with API.IR 
spectrum of working standard is concordant with the spectrum of API        
(Fig.15 to17 ). 
 
6. From the solubility data, It is found that Artemether and Lumefantrine is freely 
soluble in Dichloromethane, ethanol and insoluble in water (table 28 & 29). 
 
 
7. The λmax of pure drugs scanned in UV spectrometer in dissolution medium by 
using appropriate blank from a wavelength 200 – 400 nm shows that highest λmax 
for Artemether – 254 nm and for Lumefantrine - 335 nm ( Fig.9&10). 
 
8. The tablet was prepared by wet granulation method by varying concentration of 
excipients and subjected to compression. The formulated tablets physical 
attributes such as percentage weight variation, Hardness, DT, Friability, Assay 
all of which were found to be within pharmacopieal limits (table 44 ). 
 
9. Preparation of standard calibration curve in 0.1M methanolic HCL media, of 
both Artemether and Lumefantrine shows that highest R
2 
value 0.999 (fig.7&8). 
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10. The results of in-vitro drug release studies in water (Artemether) and in 0.1M 
HCL with 1% Benzal konium chloride (Lumefantrine) are presented in (fig.11 to 
14). Initially our aim was to select optimum concentration of excipients. Hence 
the tablets containing drug and excipients were prepared by altering the 
concentration of excipients. 
 
11. The In-vitro drug release studies of these tablets shows that the cumulative drug 
release of Artemether in last last 180 minutes more than 98 % and of 
Lumefantrine in last 60 minutes is more than 90 % as compared with innovator 
formulation (table. 45 to 52). 
 
12. The F3 formulation shows the similar dissolution profile i.e. the formulated 
tablet (F3) has higher dissolution pattern than that of the innovator tablet 
(coartem) (table. 50 to51) 
 
13. By comparing the Dissimilarity (f1) and Similarity (f2) factor with that of the 
commercial formulation follows less dissimilar and highest similarity within 
given range. (table. 50 & 51) 
 
14. Stability studies on the optimized tablet formulation at stability conditions 40 ± 
2ºC and 75 ± 5 % RH, for one month (table 65 & table 66  ) shows good stability 
in Blister packing. 
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9. CONCLUSION 
A fixed dose combination of tablet formulation of Artemether and Lumefantrine was 
successfully developed that has in-vitro drug release characteristics same as compared 
to the Conventional Coartem, Novartis Ltd., product. Moreover the developed product 
is morebetter with regards to formulation components and processing aspects. 
Final formula of Artemether and Lumefantrine tablet 
Ingredients Batch No. F3 
Lumefantrine 120.00 
Artemether  20.00 
Hydroxyl propyl cellulose 1.50 
Polysorbate 80 3.00 
Iso propyl alcohol Qs (80 ml) 
Croscarmellose sodium 5.00 
Aerosil 4.00 
Microcrystalline cellulose 80.50 
Magnesium stearate 6.00 
 
It is expected that this work will act as: 
Benchmark for treatment of acute uncomplicated malaria caused by Plasmodium 
falciparum, including malaria acquired in chloroquine-resistant areas. 
If the formulation technology is transferred for production of Artemether and 
Lumefantrine tablets in large scale then it will be cost effective in India and 
international market. 
Utilization of total amount of drug can be improved through this fixed dose 
combination technique. Hence the cost of treatment can be reduced as well as patient 
care time. 
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